



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C12P 19/34, C12Q 1/68, 1/70, C07H 19/04		A1	(11) International Publication Number: WO 97/00967  (43) International Publication Date: 9 January 1997 (09.01.97)
(21) International Application Number: PCT/US96/10729  (22) International Filing Date: 21 June 1996 (21.06.96)		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data:  08/494,216 23 June 1995 (23.06.95) US 08/540,228 6 October 1995 (06.10.95) US 08/553,936 6 November 1995 (06.11.95) US 08/612,036 7 March 1996 (07.03.96) US		Published <i>With international search report.</i>	
<p>(71) Applicant: BAYLOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza, Houston, TX 77030 (US).</p> <p>(72) Inventors: METZKER, Michael, L.; 7171 Buffalo Speedway #1621, Houston, TX 77025 (US). GIBBS, Richard, A.; 3602 Gramercy, Houston, TX 77025 (US).</p> <p>(74) Agent: BRASHEARS-MACATEE, Sarah; Fulbright &amp; Jaworski L.L.P., Suite 5100, 1301 McKinney, Houston, TX 77010-3095 (US).</p>			
<p>(54) Title: ALTERNATIVE DYE-LABELED PRIMERS, RIBONUCLEOTIDES, DEOXYRIBONUCLEOTIDES, AND DIDEOXYRIBONUCLEOTIDES FOR AUTOMATED DNA ANALYSIS AND HOMOGENEOUS AMPLIFICATION/DETECTION ASSAYS</p> <p>(57) Abstract</p> <p>Methods for the use of a class of dyes for improved DNA sequencing are provided. A new class of dyes, BODIPY® fluorophores, has been described recently. The parent heterocyclic molecule of the BODIPY® fluorophores is a dipyrrometheneboron difluoride compound which is modified to create a broad class of spectrally-discriminating fluorophores. The present invention provides methods for the use of BODIPY® fluorophore-labeled DNA for dye-primer sequencing in which the BODIPY®s are attached to the 5' end of sequencing primers, methods for DNA sequencing by the chain termination method of DNA sequencing and for internal labelling of polynucleotides by enzymatic incorporation of fluorescently-labeled ribonucleotides or deoxyribonucleotides, and provides oligonucleotides labelled with substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY®fluorophore) compounds for performing the Taqman assay. BODIPY® fluorophores have improved spectral characteristics compared to conventional fluorescein and rhodamine dyes. BODIPY® fluorophores have narrower band width, insensitivity to solvent or pH, and improved photostability, thus, BODIPY® fluorophores lead to improved DNA sequencing and/or detection in any method where electrophoresis and detection of DNA is required. Additionally, the spectral properties of the BODIPY® fluorophores are sufficiently similar in wavelength and intensity to be used with conventional equipment known in the art.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

**ALTERNATIVE DYE-LABELED PRIMERS, RIBONUCLEOTIDES,  
DEOXYRIBONUCLEOTIDES, AND DIDEOXYRIBONUCLEOTIDES  
FOR AUTOMATED DNA ANALYSIS AND HOMOGENEOUS  
AMPLIFICATION/DETECTION ASSAYS**

5

This invention was supported in part by a grant from the United States Government through the National Institutes of Health (Grant Nos. P30HG00210 (NIH) and T32HG00003 (NIH-NCHGR)). The U.S. Government has certain rights in this invention.

10

**FIELD OF THE INVENTION**

This invention relates generally to methods for the use of a class of substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY® fluorophore) compounds for improved DNA sequencing by chemical cleavage and by hybridization, labelling of DNA fragments for genetic analysis, improved DNA sequencing by the chain termination method of DNA sequencing and for internal labelling of polynucleotides by enzymatic incorporation of fluorescently-labeled ribonucleotides or deoxyribonucleotides, and performing the Taqman assay.

15

BACKGROUND

The ability to determine the sequence of DNA is critical for understanding the function and control of genes and for applying many of the basic techniques of molecular biology. Native DNA consists of two linear polymers, or strands, of nucleotides. Each strand is a chain of nucleosides linked by phosphodiester bonds. The two strands are held together in an antiparallel orientation by hydrogen bonds between complementary bases of the nucleotides of the two strands: deoxyadenosine triphosphate (A) pairs with thymidine triphosphate (T) and deoxyguanosine triphosphate (G) pairs with deoxycytidine triphosphate (C).

The development of reliable methods for sequence analysis of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) has been essential to the success of recombinant DNA and genetic engineering. When used with the other techniques of modern molecular biology, nucleic acid sequencing allows dissection of animal, plant and viral genomes into discrete genes with defined chemical structure. Since the function of a biological molecule is determined by its structure, defining the structure of a gene is crucial to the eventual useful manipulation of this basic unit of hereditary information. Once genes are isolated and characterized, they can be modified to produce desired changes in their structure that allow the production of gene products--proteins--with different properties than those possessed by the original gene products.

The development of modern nucleic acid sequencing methods involved parallel developments in a variety of techniques. One was the emergence of simple and reliable methods for cloning small to medium-sized strands of DNA into bacterial plasmids, bacteriophages, and small animal viruses. Cloning allowed the production of pure DNA in sufficient quantities to allow chemical analysis. Another was the use of gel electrophoretic methods for high resolution separation of oligonucleotides

on the basis of size. The key development, however, was the introduction of methods of generating sets of fragments of cloned, purified DNA that contain, in their collection of lengths, the information necessary to define the sequence of the nucleotides comprising the parent DNA molecules.

5 Presently there are several approaches to DNA sequence determination, see, e.g., the dideoxy chain termination method, Sanger et al., *Proc. Natl. Acad. Sci.*, 74:5463-67 (1977); the chemical degradation method, Maxam et al., *Proc. Natl. Acad. Sci.*, 74:560-564 (1977); and hybridization methods, Drmanac et al., *Genomics*, 4:114-28 (1989),  
10 Khrapko, *FEB* 256:118-22 (1989). The chain termination method has been improved in several ways, and serves as the basis for all currently available automated DNA sequencing machines. See, e.g., Sanger et al., *J. Mol. Biol.*, 143:161-78 (1980); Schreier et al., *J. Mol. Biol.*, 129:169-72  
15 (1979); Smith et al., *Nucleic Acids Research*, 13:2399-2412 (1985); Smith et al., *Nature*, 321:674-79 (1987) and U.S. Patent No. 5,171,534; Prober et al., *Science*, 238:336-41 (1987); Section II, *Meth. Enzymol.*, 155:51-334 (1987); Church et al., *Science*, 240:185-88 (1988); Swerdlow and Gesteland, *Nucleic Acids Research*, 18: 1415-19 (1989); Ruiz-Martinez et al., *Anal. Chem.*, 2851-58 (1993); Studier, *PNAS*, 86:6917-21 (1989); Kieleczawa et  
20 al., *Science*, 258:1787-91; and Connell et al., *Biotechniques*, 5:342-348 (1987).

The method developed by Sanger is referred to as the dideoxy chain termination method. In a commonly-used variation of this method, a DNA segment is cloned into a single-stranded DNA phage such as M13. These 25 phage DNAs can serve as templates for the primed synthesis of the complementary strand by conventional DNA polymerases. The primer is either a synthetic oligonucleotide or a restriction fragment isolated from the parental recombinant DNA that hybridizes specifically to a region of the M13 vector near the 3' end of the cloned insert. In each of four sequencing reactions, the primed synthesis is carried out in the presence 30 of enough of the dideoxy analog of one of the four possible

deoxynucleotides so that the growing chains are randomly terminated by the incorporation of these "deadend" nucleotides. The relative concentration of dideoxy to deoxy forms is adjusted to give a spread of termination events corresponding to all the possible chain lengths that can be resolved by gel electrophoresis. The products from each of the four primed synthesis reactions are loaded into individual lanes and are separated by polyacrylamide gel electrophoresis. Radioactive label incorporated in the growing chains are used to develop an autoradiogram image of the pattern of the DNA in each electrophoresis lane. The sequence of the deoxynucleotides in the cloned DNA is determined from an examination of the pattern of bands in the four lanes. Because the products from each of the four synthesis reactions must be run on separate gel lanes, there are problems with comparing band mobilities in the different lanes.

Turning to automated DNA sequencing machines, in general, fragments having different terminating bases can be labeled with different fluorescent dyes, which are attached either to a primer for dye-primer sequencing in which the fluorescent dyes are attached to the 5' end of the primers, e.g., Smith et al. (1987, cited above), or to the base of dideoxynucleotides for dye terminator sequencing in which the fluorescent dyes are attached to the C<sup>7</sup> position of a purine terminating base and the C<sup>6</sup> of a pyrimidine terminating base, e.g., Prober et al. (cited above). A fluorescence detector then can be used to detect the fluorophore-labeled DNA fragments. The four different dideoxy-terminated samples can be run in four separate lanes or, if labeled differentially, in the same lane. The method of Fung, et al., U.S. Patent No. 4,855,225, uses a set of four chromophores or fluorophores with different absorption or fluorescent maxima. Each of these tags is coupled chemically to the primer used to initiate the synthesis of the fragment strands. In turn, each tagged primer is then paired with one of the dideoxynucleotides and used in the primed synthesis reaction with conventional DNA polymerases. The labeled

fragments are then combined and loaded onto the same gel column for electrophoretic separation. Base sequence is determined by analyzing the fluorescent signals emitted by the fragments as they pass a stationary detector during the separation process.

5       Obtaining a set of dyes to label the different fragments is a major difficulty in automated DNA sequencing systems. First, it is difficult to find three or more dyes that do not have emission bands which overlap significantly since the typical emission band halfwidth for organic fluorescent dyes is about 40-80 nanometers (nm) and the width of the  
10      visible spectrum is only about 350-400 nm. Second, even if dyes with non-overlapping emission bands are found, the set may still be unsuitable for DNA sequencing if the respective fluorescent efficiencies are too low. For example, Pringle et al., DNA Core Facilities Newsletter, 1:15-21 (1988), present data indicating that increased gel loading cannot compensate low  
15      fluorescent efficiencies.

Another difficulty with obtaining an appropriate set of dyes is that when several fluorescent dyes are used concurrently, excitation becomes difficult because the absorption bands of the dyes are often widely separated. The most efficient excitation occurs when each dye is  
20      illuminated at the wavelength corresponding to its absorption band maximum. Thus, one often is forced to compromise between the sensitivity of the detection system and the increased cost of providing separate excitation sources for each dye. In addition, when the number  
25      of differently sized fragments in a single column of a gel is greater than a few hundred, the physiochemical properties of the dyes and the means by which they are linked to the fragments become critical because the charge, molecular weight, and conformation of the dyes and linkers must not effect adversely the electrophoretic mobilities of closely-sized fragments. Changes in electrophoretic mobility can result in extensive  
30      band broadening or reversal of band positions on the gel, thereby destroying the correspondence between the order of bands and the order

of the bases in the nucleic acid sequence. Due to the many problems associated with altered electrophoretic mobility, correction of mobility discrepancies by computer software is necessary in prior art systems. Finally, the fluorescent dyes must be compatible with the chemistry used 5 to create or manipulate the fragments. For example, in the chain termination method the dyes used to label primers and/or the dideoxy chain terminators must not interfere with the activity of the polymerase or reverse transcriptase employed.

Because of these severe constraints, only a few sets of fluorescent 10 dyes have been found that can be used in DNA sequencing, particularly automated DNA sequencing, and in other diagnostic and analytical techniques, e.g., Smith et al. (1985, cited above); Prober et al. (cited above); Hood et al., European patent application 8500960; Bergot et al. (cited above); Fung et al. (cited above); Connell et al. (cited above); Lee, 15 et al., *Nucleic Acids Research*, 20:2471-83 (1992); and Menchen et al., U.S. Patent No. 5,188,934.

In view of the above, DNA sequencing would be advanced significantly by the availability of new sets of fluorescent dyes which (1) are physiochemically similar, (2) permit detection of spatially overlapping 20 target substances, such as closely spaced bands of DNA on a gel, (3) extend the number of bases that can be determined on a single gel column by current methods of automated DNA sequencing, (4) are amenable for use with a wide range of preparative and manipulative techniques, and (5) otherwise satisfy the numerous requirements listed above. See, Bergot, et 25 al. (cited above).

Until the present invention, one problem encountered was that each fluorophore altered the "normal" electrophoretic mobility of the corresponding termination products during gel electrophoresis such that 30 software correction files were needed to generate accurate, evenly-spaced DNA sequences. See, Smith et al., *Nature*, 321:674-79 (1986) and U.S. Patent No. 5,171,534. Thus, the set of discriminating fluorophores

described in the literature is small, and the search for improved, alternative dyes has been difficult at best.

There are several different chemical modifications that have been attempted to correct for differences in gel mobility between different dye-labeled primers in automated DNA sequencing. Generally, fluorescein and its derivative dyes labeled in DNA sequencing reactions have different gel mobilities in comparison to rhodamine and its derivative dyes labeled in DNA sequencing reactions. Fluorescein and its derivative dye-labeled reactions typically move through the gel faster (sometimes greater than one base position) than rhodamine and its derivative dye-labeled reactions.

For example, if using the -21M13 universal sequencing primer, each fluorophore is coupled to the primer via different linker arm lengths. Both fluoresceins are coupled to the primer using a two-carbon amino linker arm while both rhodamines are coupled to the primer using six-carbon amino linker arm. Mobility correction software, however, is required additionally to generate properly spaced DNA termination fragments. Another example involves custom sequencing primers. These primers refer to any oligonucleotide sequence that can act as a suitable DNA sequencing primer. To all custom sequencing primers, a 5'-leader sequence (5'-CAGGA) must be coupled to the primer and custom sequencing primers must use the M13RP1 mobility correction software to generate properly-spaced DNA termination fragments. The leader sequence is the first five bases of the reverse M13RP1 sequencing primer. M13RP1 is the mobility software file used to generate properly spaced DNA termination fragments for the reverse sequencing primer.

Aside from DNA sequencing, a significant advance in DNA manipulation was the development of the polymerase chain reaction (PCR) technique as disclosed in U.S. Pat. Nos. 4,683,195; 4,683,195; and 4,800,159. The term "polymerase chain reaction" or "PCR" refers generally to the procedure involving: (1) treating extracted DNA to form single-stranded complementary strands; (2) adding a pair of oligonucleotide

primers, wherein one primer of the pair is substantially complementary to part of the sequence in the sense strand and the other primer of each pair is substantially complementary to a different part of the same sequence in the complementary antisense strand; (3) annealing the paired primers to the complementary sequence; (4) simultaneously extending the annealed primers from a 3' terminus of each primer to synthesize an extension product complementary to the strands annealed to each primer wherein said extension products after separation from the complement serve as templates for the synthesis of an extension product for the other primer of each pair; (5) separating said extension products from said templates to produce single-stranded molecules; and (6) amplifying said single-stranded molecules by repeating at least once said annealing, extending and separating steps.

Detection methods generally employed in standard PCR techniques use a labeled probe with the amplified DNA in a hybridization assay. Other assays include the use of fragment length polymorphism (PCR FLP), hybridization to allele-specific oligonucleotide (ASO) probes (Saiki et al., *Nature* 324:163 (1986)), or direct sequencing via the dideoxy method (using amplified DNA rather than cloned DNA). The standard PCR technique operates by replicating a DNA sequence positioned between two primers, providing as the major product of the reaction a DNA sequence of discrete length terminating with the primer at the 5' end of each strand. Thus, insertions and deletions between the primers result in product sequence of different lengths, which can be detected by sizing the product in PCR-FLP. In an example of ASO hybridization, the amplified DNA is fixed to a nylon filter (by, for example UV irradiation) in a series of "dot blots", then allowed to hybridize with an oligonucleotide probe labeled with HRP under stringent conditions. After washing, tetramethylbenzidine (TMB) and hydrogen peroxide are added: HRP oxidizes the hydrogen peroxide, which in turn oxidizes the TMB to a blue precipitate, indicating hybridized probe.

While the PCR technique as presently practiced is an extremely powerful method for amplifying nucleic acid sequences, the detection of the amplified material requires additional manipulation and subsequent handling of the PCR products to determine whether the target DNA is 5 present. It is desirable to decrease the number of subsequent handling steps required currently for the detection of amplified material.

Holland, et al., *PNAS* 88:7276-7280 (1991) describe an assay known as a Taqman assay. The 5' → 3' exonuclease activity of Taq polymerase is employed in a polymerase chain reaction product detection system to 10 generate a specific detectable signal concomitantly with amplification. An oligonucleotide probe, nonextendable at the 3' end, labeled at the 5' end, and designed to hybridize within the target sequence, is introduced into the polymerase chain reaction assay. Annealing of the probe to one of the polymerase chain reaction product strands during the course of 15 amplification generates a substrate suitable for exonuclease activity. During amplification, the 5' → 3' exonuclease activity of Taq polymerase degrades the probe into smaller fragments that can be differentiated from undegraded probe. The assay is sensitive and specific and is a significant improvement over more cumbersome detection methods. A version of this 20 assay is also described in Gelfand et al., in U.S. Patent No. 5,210,015. U.S. Patent No. 5,210,015 to Gelfand, et al., and Holland, et al., *PNAS* 88:7276-7280 (1991) are hereby incorporated by reference.

Further, U.S. Pat. No. 5,491,063 to Fisher, et al., provides a 25 Taqman-type assay. The method of Fisher et al. provides a reaction that results in the cleavage of single-stranded oligonucleotide probes labeled with a light-emitting label wherein the reaction is carried out in the presence of a DNA binding compound that interacts with the label to modify the light emission of the label. The method utilizes the change in light emission of the labeled probe that results from degradation of the 30 probe. The methods are applicable in general to assays that utilize a reaction that results in cleavage of oligonucleotide probes, and in

-10-

particular, to homogeneous amplification/detection assays where hybridized probe is cleaved concomitant with primer extension. A homogeneous amplification/detection assay is provided which allows the simultaneous detection of the accumulation of amplified target and the sequence-specific detection of the target sequence. U.S. Pat. No. 5,491,063 to Fisher, et al. is hereby incorporated by reference. Further, Lee, et al., *NAR* 21:3761-3766 (1993) describe nick translation PCR using fluorogenic probes. In this assay, two probes were used to detect mutant and wildtype cystic fibrosis alleles. Lee, et al., *NAR* 21:3761-3766 (1993) is incorporated herein by reference.

A new class of dyes, BODIPY® fluorophores, has been recently described. See, Haugland, et al., *Molecular Probes: Handbook of Fluorescent Probes and Research Chemicals*, pp. 24-32, and U.S. Patent No. 4,774,339. The parent heterocyclic molecule of the BODIPY® fluorophores is a dipyrrometheneboron difluoride compound and which is modified to create a broad class of spectrally-discriminating fluorophores, see Figure 1. The conventional naming of these dyes is BODIPY® followed by their approximate absorption/emission maxima, e.g., BODIPY® 530/550. The present invention provides for BODIPY® fluorophores for methods for DNA sequencing by chemical cleavage, hybridization, chain termination, for genetic analysis and for performing the Taqman assay.

In addition to the specifically-cited references above, additional prior art techniques include the following:

U.S. Patent No. 4,318,846 to Khanna et al. is drawn to diether symmetrically-substituted fluoresceins having at least one anionic group and a linking functionality. Depending on the site of substitution, the compounds can be used as fluorescers absorbing at wavelengths in excess of 500 nm. The compounds can be used as labels in fluorescent immunoassays.

-11-

U.S. Patent No. 4,811,218 to Hunkapiller et al. is drawn to a real-time, automated nucleic acid sequencing apparatus which permits more than one clone to be sequenced at the same time.

5 U.S. Patent No. 4,855,225 to Fung et al., is drawn to a method for detecting up to four sets of oligonucleotides that have been differentially-labeled with fluorophores, two of the sets with substituted fluoresceins and two sets with substituted rhodamines, and separated by gel electrophoresis.

10 U.S. Patent No. 5,366,860 to Bergot et al., is drawn to a method for detecting up to four sets of oligonucleotides that have been differentially-labeled with fluorophores, all rhodamines with different substitutions, and separated by gel electrophoresis.

15 U.S. Patent No. 5,188,934 to Menchen, et al., is drawn to a method for detecting up to four sets of oligonucleotides that have been differentially-labeled with fluorophores, all fluoresceins with different substitutions, and separated by gel electrophoresis.

20 U.S. Patent No. 5,171,534 to Smith et al. describes a system for the electrophoretic analysis of DNA fragments produced in DNA sequencing operations. The system comprises a source of chromophore or fluorescent tagged DNA fragments, a zone for contacting an electrophoresis gel, means for introducing said tagged DNA fragments to said zone and photometric means for monitoring the tagged DNA fragments as they move through the gel.

25 U.S. Patent No. 5,366,603 is drawn to automatic DNA sequencing wherein the DNA is marked with near infrared fluorescent dyes.

30 U.S. Patent No. 5,241,060 to Englehardt, et al., is drawn to labeled nucleotides and polynucleotides with the formula PM-SM-BASE-Sig, where PM is a phosphate moiety, SM is a sugar moiety, BASE is a purine, pyrimidine or 7-deazapurine moiety, and Sig is a detectable moiety that is covalently attached to the BASE entity at a position other than the C<sup>5</sup> position when BASE is a pyrimidine, at a position other than the C<sup>8</sup>

-12-

position when BASE is a purine and at a position other than the C' position when BASE is a 7-deazapurine.

U.S. Patent No. 4,755,458 to Rabbani, et al., is drawn to compositions for detecting the presence of a nucleotides sequence of interest. The composition includes a first polynucleotide molecule is substantially complementary to and capable of hybridizing with a specific sequence of interest and which is labeled with a first detectable marker; a second polynucleotide molecule is not substantially complementary to and is not capable of hybridizing with the specific sequence of interest and is labeled with the same, first detectable marker; and a third polynucleotide molecule that is substantially complementary to or substantially identical to the second polynucleotide but is unlabeled or labeled with a second detectable marker.

U.S. Patent No. 5,151,507 to Hobbs, et al., drawn to alkynylamino-nucleotides useful as chain terminating substrates for DNA sequencing.

U.S. Patent No. 5,274,113 to Kang, et al., is drawn to derivatives of dipyrrometheneboron difluoride fluorescent dyes that can be attached to nucleic acids, proteins, carbohydrates and other biologically-derived materials. The compounds of Kang, et al., show various functional groups for attachment of the dipyrrometheneboron difluoride fluorescent dyes to the biologically-derived materials.

#### SUMMARY OF THE INVENTION

BODIPY® fluorophores have improved spectral characteristics compared to conventional fluorescein and rhodamine dyes. The BODIPY® fluorophores have narrower band width, insensitivity to solvent or pH, and improved photostability. Thus, the use of BODIPY® fluorophores leads to improved DNA sequencing or analysis of DNA fragments in any method where electrophoresis of BODIPY®-labeled DNA is required.

-13-

It is an object of the present invention to provide methods for the use of a class of dyes particularly suited for DNA sequencing.

It is an additional particular object of the present invention to provide methods for the use of BODIPY® fluorophores in the chemical 5 cleavage method of DNA sequencing.

It is a particular object of the present invention to provide methods for the use of BODIPY® fluorophores for any method of DNA sequencing in which polynucleotide products of the sequencing reaction are 5'-end-labelled with said BODIPY® fluorophores.

10 It is a further object of the present invention to provide methods for the use of BODIPY® fluorophores which have been chemically-modified so that a BODIPY® fluorophore can be used to replace a prior art 5'-end-labelled fluorophore in DNA sequencing and conventional software may be used. BODIPY® fluorophores can be used in one out of the four 15 reactions, two out of the four reactions or three out of the four reactions or in all four reactions.

If BODIPY® fluorophores are used in four out of the four reactions, a particular object of the present invention is to provide methods for the use of BODIPY® fluorophores for automated DNA sequencing which, since 20 the particular BODIPY® fluorophores alter the mobility of the corresponding termination products *in the same way*, nullifies the need for software correction to generate evenly-spaced DNA sequences.

An additional object of the present invention is to provide methods for the use of BODIPY® fluorophores for DNA sequencing wherein the 25 BODIPY® fluorophore is attached at the 5' end of the polynucleotide product of the sequencing reaction and at the 3' end or at one or more internal positions of the products of the sequencing reaction.

Thus, in accomplishing the foregoing objects, there is provided a 30 method for analysis of DNA fragments wherein said DNA fragments are labelled with at least one BODIPY® fluorophore. Further, in accomplishing the foregoing objects, there is provided in accordance with

-14-

the present invention, a method for distinguishing polynucleotides having different 3'-terminal dideoxynucleotides in any method of DNA sequencing requiring electrophoresis of the products of the sequencing reactions, the method comprising the steps of: forming a mixture of a first,  
5 a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a 3'-terminal dideoxyadenosine and being labeled with a first fluorophore; each polynucleotide in the second class having a 3'-terminal dideoxycytidine and being labeled with a second fluorophore; each polynucleotide in the third class having a 3'-  
10 terminal dideoxyguanosine and being labeled with a third fluorophore; and each polynucleotide in the fourth class having a 3'-terminal dideoxythymidine and being labeled with a fourth fluorophore; wherein at least one of said fluorophores is a BODIPY® fluorophore, and, wherein if said first, second, third and fourth fluorophores are all different, said  
15 polynucleotides can be electrophoresed in a same or different lanes; or wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the  
20 bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.  
25

It is another, particular object of the present invention to provide BODIPY® fluorophores for DNA sequencing wherein the BODIPY® fluorophore is attached to a nucleotide at a 3' BODIPY® position.

It is a further object of the present invention to provide methods for the use of a class of dyes particularly suited for the chain termination method of DNA sequencing. It is also an object of the present invention to provide methods for labelling internally RNA or DNA fragments by enzymatic incorporation of dye-labeled ribonucleotides or deoxynucleotides. The labeled fragments may then be analyzed.  
30

Further in accomplishing the foregoing objects, there is provided a method for analysis of DNA fragments wherein said DNA fragments are labeled with at least one BODIPY® fluorophore. In accomplishing the foregoing objects, there is provided in accordance with the present invention, a method for distinguishing polynucleotides having different 3'-terminal dideoxyribonucleotides in any method of chain termination DNA sequencing, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a 3'-terminal dideoxyadenosine triphosphate, said 3'-terminal dideoxyadenosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a first BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the second class having a 3'-terminal dideoxycytidine triphosphate, said 3'-terminal dideoxycytidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a second BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the third class having a 3'-terminal dideoxyguanosine triphosphate, said 3'-terminal dideoxyguanosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a third BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the fourth class having a 3'-terminal dideoxythymidine triphosphate, said 3'-terminal dideoxythymidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a fourth BODIPY® fluorophore that contains at least one reactive functional group; wherein if said first, second, third and fourth BODIPY® fluorophores are all different, said polynucleotides can be electrophoresed in a same or a different lane; or

-16-

wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

Additionally, in accomplishing the foregoing objects there is provided a method for distinguishing polynucleotides having different ribonucleotides in any method of labelling polynucleotides by enzymatic incorporation, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having an adenosine triphosphate, said adenosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a first BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the second class having a cytidine triphosphate, said cytidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a second BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the third class having a guanosine triphosphate, said guanosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a third BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the fourth class having a uracil, said uracil triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a fourth BODIPY® fluorophore that contains at least one reactive functional group; wherein if said first, second, third and fourth BODIPY®

-17-

fluorophores are all different, said polynucleotides can be electrophoresed in a same or a different lane; or wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes;

5       electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

10       Additionally, in accomplishing the foregoing objects, there is provided a method for distinguishing polynucleotides having different deoxyribonucleotides in any method of labelling polynucleotides by enzymatic incorporation, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a deoxyadenosine triphosphate, said deoxyadenosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a first BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the second class having a deoxycytidine triphosphate, said deoxycytidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a second BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the third class having a deoxyguanosine triphosphate, said deoxyguanosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a third BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the fourth class having a deoxythymidine triphosphate, said deoxythymidine triphosphate being attached at the 5 position of the pyrimidine to a 3-

15

20

25

30

-18-

amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a fourth BODIPY® fluorophore that contains at least one reactive functional group; wherein if said first, second, third and fourth BODIPY® fluorophores are all different, said polynucleotides can be 5 electrophoresed in a same or a different lane; or wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the bands on the 10 gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

It is an additional object of the present invention to provide oligonucleotides labelled with substituted 4,4-difluoro-4-bora-3A,4A-diaza-15 s-indacene (BODIPY® fluorophore) compounds for performing the Taqman assay.

Other and further objects, features and advantages will be apparent and the invention more readily understood from a reading of the following specification and by reference to the accompanying drawings forming a 20 part thereof, wherein the examples of the presently preferred embodiments of the invention are given for the purposes of disclosure.

#### DESCRIPTION OF THE DRAWINGS

Figure 1: Chemical structures of several DNA sequencing fluorophores are shown.

25 Figure 2: 5'-end modifications of (A) single dye-labeled primers: R865, R932, R930, and R931; and (B) double dye-labeled primers FET-3 and BET-3 are shown. Since different protecting groups block the linker arm amines, BET primers were first labeled internally with BODIPY®

-19-

503/512. Following removal of the monomethoxytrityl group, BET primers were end-labeled with the BODIPY® dye set. The (CH<sub>2</sub>)<sub>n</sub> for BET primers correspond to (CH<sub>2</sub>)<sub>3</sub> for BODIPY® 581/591 and (CH<sub>2</sub>)<sub>6</sub> for BODIPY® 503/512, BODIPY® 523/547, and BODIPY® 564/570 dyes.

5       Figure 3: Depicts the results of a dye-labeled substitution experiment. DNA sequencing reactions were generated by solid-phase *Bst* sequencing. The region shown corresponds to approximately 230 to 240 bases (Blue), 160 to 170 bases (Green), 290 to 300 bases (Black), and 200 to 210 bases (Red) in the sequencing read. 373A raw files were analyzed  
10 by the ABI sequencing analysis version 2.1.0 software program using the ABI50 (standard) base caller with the M13RP1 mobility correction file. The l max (parentheses) for dye-primers was determined using a Model F-4010 fluorescence spectrophotometer (Hitachi, Ltd) in 1X TBE buffer (0.089 M Tris-borate, 0.002 M Na<sub>2</sub>EDTA) containing 7 M urea. Signal  
15 strength was measured using a 373A sequencer (373A) or using a fluorescence spectrophotometer (Spec.). 373A measurements were determined by M13 cycling sequencing reactions of four different molecular clones. The relative intensity values were determined by normalizing the BODIPY® dye signal to the remaining dye signals and  
20 comparing it to its normalized conventional dye signal. Spec. measurements were performed in duplicate and determined by comparing the fluorescence intensity at l max of BODIPY® dye-primers to conventional dye-primers. FAM and BODIPY® 503/512 were excited at 488 nm and all remaining dyes were at 514 nm.

25       Figure 4: Demonstrates that BODIPY® dye-labeled primers do not require gel mobility correction. -21M13 primers and BODIPY® primers were used to sequence two different M13 clones by cycle sequencing. 21M13 primers contain FAM-"C", JOE-"A", TAMRA-"G", AND ROX-"T" dye labels and BODIPY® primers contain BODIPY® 503/512-"C", BODIPY®

-20-

530/550-"A", BODIPY® 564/570-"G", BODIPY® 581/591-"T" dye labels. Arrows above the sequence chromatograms highlight base calling errors, and the approximate base regions from the primer peak are listed.

5 **Figure 5:** A general synthetic scheme for end labeling (Route I) and internal labeling (Route II) BODIPY® phosphoramidites is depicted. For specific BODIPY® chemical structures, see **Figure 1**.

**Figure 6:** Depicts normalized emission spectra of four conventional dye-primers and BODIPY® dye-primers.

10 **Figure 7:** Chemical structures of AP-3 nucleotides are shown, where R<sub>1</sub>=OH and R<sub>2</sub>=OH for ribonucleotides; R<sub>1</sub>=OH and R<sub>2</sub>=H for deoxynucleotides; and R<sub>1</sub>=H and R<sub>2</sub>=H for dideoxyribonucleotides.

15 **Figure 8:** (A) Double dye-labeled primers. Since different protecting groups block the linker arm amines, BODIPY energy transfer (BET) primers were first labeled internally with BODIPY 503/512, BODIPY 523/547 or BODIPY 530/550. After removal of the monomethoxytrityl group, BET primers were end-labeled with the BODIPY dye set. For BODIPY 503/512, BODIPY 523/547 or BODIPY 530/550 dyes, n = 6, R1 = CH<sub>3</sub>, and R2 = (CH<sub>2</sub>)<sub>n</sub>NHBODIPY. For BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, and BODIPY 589/616 dyes, n = 3, R1 = (CH<sub>2</sub>)<sub>n</sub>NHBODIPY and R2 = CH<sub>3</sub>. Primers are blocked at the 3' end with a modified amino group (NH<sub>2</sub>) to prevent polymerase extension of the probe. (B) Diagnostic application in determining reverse transcriptase resistance to antiviral drug therapy in patients infected with human immunodeficiency virus type-1 (HIV-1). Drug resistant markers have been previously described by B.A. Larder, "Reverse Transcriptase", A.M. Skalka and S.P. Goff, Eds., pp. 205-222 (Cold Spring Harbor Laboratory Press, 1993). BET probe labeled with

-21-

BODIPY 503/512 is specific for the wild-type sequence and BET probe labeled with BODIPY 523/547 is specific for the drug resistance sequence.

The drawings and figures are not to scale and certain features mentioned may be exaggerated in scale or shown in schematic form in the interest of clarity and conciseness.

#### DETAILED DESCRIPTION OF THE INVENTION

It will be apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and the spirit of the invention.

As used herein, "BODIPY®" shall refer to a class of modified, spectrally-discriminating fluorophores wherein the parent heterocyclic molecule is a dipyrrometheneboron difluoride compound. Some BODIPY® fluorophores of the present invention have a BODIPY linker at the 3 position of the BODIPY® molecule that contains at least one functional group capable of attachment to AP-3 ribonucleotides, AP-3 deoxyribonucleotides or AP-3 dideoxyribonucleotides. Specific BODIPY® fluorophores useful in the present invention include BODIPY®s with adsorption maxima of about 450 to 700, and emission maxima of about 450 to 700. Preferred embodiments include BODIPY®s with adsorption maxima of about 480 to 650, and emission maxima of about 480 to 650. Examples of preferred embodiment BODIPY®s include BODIPY® 503/512-SE (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid), BODIPY® 523/547 (4,4-difluoro-5-phenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid), BODIPY® 530/550 (4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid), BODIPY® 558/568 (4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid), BODIPY® 564/570 (4,4-difluoro-5-styryl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid), BODIPY® 576/589 (4,4-difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-

diaza-s-indacene-3-propionic acid), BODIPY® 581/591 (4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) and BODIPY® 589/616 (6-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)hexanoic acid).

5 As used herein, "DNA sequencing" refers to the process of determining the nucleic acid sequence of a DNA strand of interest.

As used herein "automated DNA sequencing" refers to determining the sequence of a DNA strand of interest using an apparatus comprising an area having an electrophoresis gel, means for introducing labeled DNA fragments to the gel area, and photometric means for monitoring said labeled DNA fragments as they move through the gel. "Automated DNA sequencer" refers to the instrument which is able to perform automated DNA sequencing.

15 As used herein, "sequencing primer" means a synthetic oligonucleotide, restriction fragment, enzymatically-synthesized DNA fragment, or the like which hybridizes specifically to a region proximate to the region of DNA to be sequenced. "Universal sequencing primer" refers to commonly-used primers known in the art, generally one that hybridizes specifically to a region of the M13 vector near the 5' end of the cloned insert. Specific examples of universal sequencing primers known in the art are -21M13, M13-40 and -36M13.

20 As used herein, "5' position" refers to the 5' position on the deoxyribose moiety of a polynucleotide.

25 As used herein, "3' position" refers to the 3' position on the deoxyribose moiety of a nucleotide.

As used herein, "base attachment" or "dye-terminator" refers to a molecule, particularly a fluorescent dye, attached to the C<sup>7</sup> position of a purine terminating base or the C<sup>5</sup> of a pyrimidine terminating base.

30 As used herein, "AP-3" or "AP-3 nucleotide" refers to the 3-amino-1-propynyl linker attached to the 5 position of pyrimidines or the 7 position of 7-deazapurines. See Figure 7.

As used herein, "BODIPY® linker" or "BODIPY® functional group" refers to a substituted or unsubstituted alkyl containing one to thirty carbons and at least one functional group. Two different BODIPY® linkers are illustrated in Figure 1.

5 As used herein, "FAM" shall refer to 5-carboxy-fluorescein, "JOE" shall refer to 2',7'-dimethoxy-4',5'-dichloro-6-carboxy-fluorescein, "TAMRA" shall refer to N,N,N',N'-tetramethyl-6-carboxy-rhodamine, "ROX" shall refer to 6-carboxy-X-rhodamine.

10 As used herein, electrophoresis "lanes" or "tracks" or "columns" refers to the particular path in the electrophoretic medium in which the sequencing products are run. For example, the sequencing products terminating in dideoxyadenosine, dideoxycytidine, dideoxyguanosine or dideoxythymidine may be run in four separate lanes, or, if labeled differentially, in the same lane.

15 As used herein, "linkers" or "linker arms" refers to molecules that tether a dye to a primer. Typical linker molecules include alkanes of various lengths.

As used herein, "automated GeneScanner" refers to an instrument capable of performing analysis of fluorescently-labeled DNA or RNA.

20 As used herein, "Taqman" or "Taqman assay" refers to assays that utilize the 5' ~ 3' exonuclease activity of Taq polymerase in a polymerase chain reaction to generate a specific detectable signal concomitantly with amplification. An oligonucleotide probe, nonextendable at the 3' end, labeled at the 5' end, and designed to hybridize within the target sequence, is introduced into the polymerase chain reaction assay. Annealing of the probe to one of the polymerase chain reaction product strands during the course of amplification generates a substrate suitable for exonuclease activity. During amplification, the 5' ~ 3' exonuclease activity of Taq polymerase degrades the probe into smaller fragments that can be differentiated from undegraded probe. The assay is sensitive and specific and is a significant improvement over more cumbersome detection

methods. In one such assay, the oligonucleotide that is degraded has at least two light-emitting fluorophores attached. The fluorophores interact with each other to modify (quench) the light emission of the fluorophores. The 5'-most fluorophore is the quencher fluorophore. The 3'-most fluorophore is the quenched fluorophore. In another type of Taqman assay, an oligonucleotide probe is labeled with a light-emitting quenched fluorophore wherein the reaction is carried out in the presence of a DNA binding compound (quenching agent) that interacts with the fluorophore to modify the light emission of the label.

As used herein, "labeled oligonucleotide" refers to the oligonucleotide in the Taqman assay that is labeled with at least two BODIPY® fluorophores.

As used herein, "quenched" refers to the interaction of the at least two BODIPY® fluorophores on the labeled oligonucleotide wherein when both BODIPY® fluorophores are present on the labeled oligonucleotide, fluorescence of either fluorophore is not detected.

As used herein, "quencher fluorophore" refers to the BODIPY® fluorophore at a position most 5' on the labeled oligonucleotide.

As used herein, "quenched fluorophore" refers to the BODIPY® fluorophore at a position most 3' on the labeled oligonucleotide.

As used herein, "quencher agent" refers to intercalating compounds and the like similar to ethyldium bromide for use in a Taqman assay similar to that used in the method of Fisher, et al., U.S. Pat. No. 5,491,063.

One novel aspect of the present invention is to provide a method for distinguishing polynucleotides having different 3' -terminal dideoxynucleotides in any method of DNA sequencing requiring electrophoresis of the products of the sequencing reactions, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a 3'-terminal dideoxyadenosine and being labeled at the 5'

position with a first fluorophore; each polynucleotide in the second class having a 3'-terminal dideoxycytidine and being labeled at the 5' position with a second fluorophore; each polynucleotide in the third class having a 3'-terminal dideoxyguanosine and being labeled at the 5' position with a third fluorophore; and each polynucleotide in the fourth class having a 3'-terminal dideoxythymidine and being labeled at the 5' position with a fourth fluorophore; wherein at least one of said fluorophores is a BODIPY® fluorophore, and, wherein if said first, second, third and fourth fluorophores are all different, said polynucleotides can be electrophoresed in a same or a different lane; or wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

Another aspect of the present invention allows BODIPY® fluorophores to be used in combination with prior art fluorophores and commercially-available software. This method involves distinguishing polynucleotides having different 3'-terminal dideoxynucleotides in the chain termination method of DNA sequencing, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a 3'-terminal dideoxyadenosine and being labeled at the 5' position with BODIPY® 523/547, BODIPY® 530/550 or JOE; each polynucleotide in the second class having a 3'-terminal dideoxycytidine and being labeled at the 5' position with BODIPY® 503/512 or FAM; each polynucleotide in the third class having a 3'-terminal dideoxyguanosine and being labeled at the 5' position with BODIPY® 558/568, BODIPY® 564/570 or TAMRA; and each polynucleotide in the fourth class having a 3'-terminal

-26-

dideoxythymidine and being labeled at the 5' position with BODIPY® 581/591, BODIPY® 589/616 or ROX; wherein at least one of the classes is labeled with a BODIPY® fluorophore; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

In another aspect of the present invention, there is provided a method of distinguishing polynucleotides having different 3'-terminal dideoxynucleotides in the chain termination method of DNA sequencing, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a 3'-terminal dideoxyadenosine and being labeled at the 5' position with a first BODIPY® fluorophore; each polynucleotide in the second class having a 3'-terminal dideoxycytidine and being labeled at the 5' position with a second BODIPY® fluorophore; each polynucleotide in the third class having a 3'-terminal dideoxyguanosine and being labeled at the 5' position with a third BODIPY® fluorophore; and each polynucleotide in the fourth class having a 3'-terminal dideoxythymidine and being labeled at the 5' position with a fourth BODIPY® fluorophore; wherein said first, second, third and fourth BODIPY® fluorophores are all different; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam bands of said gel, said illumination beam being capable of causing said BODIPY® fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the dyes.

In a preferred embodiment, said BODIPY® fluorophores have an adsorption maxima of about 450 to 700, and an emission maxima of about 450 to 700. In a more preferred embodiment, said BODIPY® fluorophores have adsorption maxima of about 500 to 625, and an emission maxima of about 500 to 625.

In one aspect of the present invention, said 3'-terminal dideoxyadenosine is labeled at the 5' position with BODIPY® 523/547; said 3'-terminal dideoxycytidine is labeled at the 5' position with BODIPY® 503/512; said 3'-terminal dideoxyguanosine is labeled at the 5' position with BODIPY® 564/570; and said 3'-terminal dideoxythymidine is labeled at the 5' position with BODIPY® 581/591. Labeling the polynucleotides in this manner allows for the use of conventional, commercially-available software. However, it should be clear that one skilled in the art of computer software design that software could be altered such that the software could read different BODIPY® dyes attached to different classes of polynucleotides by way of different linker arm chemistries.

In a preferred embodiment, said chain termination method of DNA sequencing is performed by an automated DNA sequencing instrument.

In another preferred embodiment, the method of the present invention further includes the step of extending from a primer a plurality of polynucleotides by means of a DNA polymerase suitable for DNA sequencing or a reverse transcriptase suitable for DNA sequencing in the presence of dideoxyadenosine triphosphate, dideoxycytosine triphosphate, dideoxyguanosine triphosphate, and dideoxythymidine triphosphate to form said first, second, third, and fourth classes of polynucleotides.

In another preferred embodiment of the present invention, said DNA polymerase is selected from the group of ThermoSequenase, Klenow fragment, Sequenase®, *Bst* DNA polymerase, AmpliTaq® DNA polymerase, *Pfu*(exo-)DNA polymerase, *rTth* DNA polymerase or Vent(exo-)®DNA polymerase, and said reverse transcriptase is selected from the group of AMV-RT or M-MuLV-RT. In the case of RNA, RNA polymerase is used.

In another embodiment of the present invention, said BODIPY® fluorophores are coupled to a primer suitable for sequencing by linkers. In a more preferred embodiment of this aspect of the present invention, said linker arms are selected from the group of (CH<sub>2</sub>)<sub>3</sub>, (CH<sub>2</sub>)<sub>6</sub>, and (CH<sub>2</sub>)<sub>12</sub>.

In yet another aspect of the present invention, said polynucleotide is labeled with more than one fluorophore, wherein said fluorophores include at least one BODIPY® fluorophore and at least one additional fluorophore. In a more preferred embodiment of this aspect of the invention, said additional fluorophore has an adsorption maxima of about 5 475 to about 650. In another embodiment of this aspect of the present invention, said additional fluorophore is a BODIPY® fluorophore or FAM.

In an additional aspect to the present invention, methods are provided for the use of BODIPY® fluorophores for DNA sequencing wherein the BODIPY® fluorophore is attached at the 5' end of the products of the sequencing reaction and at the 3' end of the product of the sequencing reaction or at one or more internal positions of the products of the sequencing reaction.

In another aspect of the present invention there is provided a method for distinguishing polynucleotide sequences in a hybridization method of DNA sequencing, said method comprising the steps of: synthesizing a first, a second, a third and a fourth class of oligonucleotides, wherein all of said classes of oligonucleotides have a same length, said first, second, third and fourth classes of oligonucleotides differ from the oligonucleotides of each other class by one nucleotide base at a 3', a 5' or an internal position, and each oligonucleotide of the first class has a deoxyadenosine at said position and is labeled at the 5' position with a first fluorophore; each oligonucleotide in the second class has a deoxycytidine at said position and is labeled at the 5' position with a second fluorophore; each oligonucleotide in the third class having a deoxyguanosine at said position and is labeled at the 5' position with a third fluorophore; and each oligonucleotide in the fourth class has a deoxythymidine at said position and is labeled at the 5' position with a fourth fluorophore; wherein at least one of said fluorophores is a BODIPY® fluorophore; hybridizing said oligonucleotides to a single-stranded DNA target immobilized to a solid support, wherein said solid

support is in a grid format, to form a hybridized product; washing said hybridized product to remove any unhybridized oligonucleotide or target; illuminating with an illumination beam the solid support, said illumination beam being capable of causing said BODIPY® fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the dyes.

In an important aspect of the present invention, there is provided a method for genetic analysis of DNA fragments wherein said DNA fragments are labelled with at least one BODIPY® fluorophore.

Another important and novel aspect of the present invention is to provide a method for distinguishing polynucleotides having different 3'-terminal dideoxyribonucleotides in any method of chain termination DNA sequencing, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a 3'-terminal dideoxyadenosine triphosphate, said 3'-terminal dideoxyadenosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a first BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the second class having a 3'-terminal dideoxycytidine triphosphate, said 3'-terminal dideoxycytidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a second BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the third class having a 3'-terminal dideoxyguanosine triphosphate, said 3'-terminal dideoxyguanosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a third BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the fourth class having a 3'-terminal dideoxythymidine triphosphate, said 3'-

-30-

terminal dideoxythymidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a fourth BODIPY® fluorophore that contains at least one reactive functional group; wherein if said first,  
5 second, third and fourth BODIPY® fluorophores are all different, said polynucleotides can be electrophoresed in a same or a different lane; or wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes; electrophoretically separating on a gel  
10 by size the polynucleotides; illuminating with an illumination beam the bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

Yet another embodiment of the present invention provides for the  
15 method of distinguishing polynucleotides having different ribonucleotides in any method of labelling polynucleotides by enzymatic incorporation, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having an adenosine triphosphate, said adenosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a first BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the second class having a cytidine triphosphate, said cytidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a second BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the third class having a guanosine triphosphate, said guanosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker  
20 at a 3 position of a third BODIPY® fluorophore that contains at least one reactive functional group; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

25

30

reactive functional group; each polynucleotide in the fourth class having a uracil triphosphate, said uracil triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a fourth BODIPY® fluorophore that contains at least one reactive functional group; wherein if said first, second, third and fourth BODIPY® fluorophores are all different, said polynucleotides can be electrophoresed in a same or a different lane; or wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

In another embodiment of the present invention, there is provided a method for distinguishing polynucleotides having different deoxyribonucleotides in any method of labelling polynucleotides by enzymatic incorporation, the method comprising the steps of: forming a mixture of a first, a second, a third, and a fourth class of polynucleotides, each polynucleotide in the first class having a deoxyadenosine triphosphate, said deoxyadenosine triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a first BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the second class having a deoxycytidine triphosphate, said deoxycytidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a second BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the third class having a deoxyguanosine triphosphate, said deoxyguanosine

triphosphate being attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a third BODIPY® fluorophore that contains at least one reactive functional group; each polynucleotide in the fourth class having a deoxythymidine triphosphate, said deoxythymidine triphosphate being attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY® linker at a 3 position of a fourth BODIPY® fluorophore that contains at least one reactive functional group; wherein if said first, second, third and fourth BODIPY® fluorophores are all different, said polynucleotides can be electrophoresed in a same or a different lane; or wherein if any of said first, second, third or fourth fluorophores are the same, said polynucleotides labeled with said same fluorophores are electrophoresed in separate lanes; electrophoretically separating on a gel by size the polynucleotides; illuminating with an illumination beam the bands on the gel, the illumination beam being capable of causing the fluorophores to fluoresce; and identifying the classes of polynucleotides in the bands by the fluorescence or absorption spectrum of the fluorophores.

In one aspect of the present invention, said adenosine triphosphate, deoxyadenosine triphosphate or 3'-terminal dideoxyadenosine triphosphate is labeled with BODIPY® 523/547 or BODIPY® 530/550; said cytidine triphosphate, deoxycytidine triphosphate or 3'-terminal dideoxycytidine triphosphate is labeled with BODIPY® 576/589, BODIPY® 581/591, or BODIPY® 589/616; said guanosine triphosphate, deoxyguanosine triphosphate or 3'-terminal dideoxyguanosine triphosphate is labeled with BODIPY® 503/512; and said uracil triphosphate, deoxythymidine triphosphate or 3'-terminal dideoxythymidine triphosphate is labeled with BODIPY® 558/568 or BODIPY® 564/570. Labelling the polynucleotides in this manner allows for the use of conventional, commercially-available software. However, it should be clear that one skilled in the art of computer software design

that software could be altered such that the software could read different BODIPY® dyes attached to different classes of polynucleotides.

Another aspect of the present invention allows BODIPY® fluorophores to be used in combination with prior art fluorophores and commercially-available software.

In another preferred embodiment, said internal labelling is performed by an automated GeneScanner.

Another important and novel aspect of the present invention is to provide an oligonucleotide substituted with at least two 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY®) fluorophores for performing a Taqman assay, wherein a first 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY®) fluorophore is a quencher fluorophore and a second 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY®) fluorophore is a quenched fluorophore.

A preferred embodiment of this aspect of the present invention provides BODIPY® 564/570 (4,4-difluoro-5-styryl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quencher fluorophore.

An additional preferred embodiment of the present invention provides BODIPY® 576/589 (4,4-difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quencher fluorophore.

A further preferred embodiment of the present invention provides BODIPY® 581/591 (4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quencher fluorophore.

Another preferred embodiment of the present invention provides BODIPY® 558/568 (4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quencher fluorophore.

Yet a further preferred embodiment of the present invention provides BODIPY® 581/591 (4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quencher fluorophore.

An additional preferred embodiment of the present invention provides BODIPY® 503/512-SE (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quenched fluorophore.

Yet another preferred embodiment of the present invention provides 5 BODIPY® 523/547 (4,4-difluoro-5-phenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quenched fluorophore.

Another preferred embodiment of the present invention provides BODIPY® 530/550 (4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) as a quenched fluorophore.

10 Another aspect of the present invention provides an oligonucleotide substituted with at least one 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY®) fluorophores for performing a Taqman assay, wherein said at least one 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY®) fluorophore is a quenched fluorophore and a quencher agent is present in 15 said Taqman assay. Any of the quenched (BODIPY®) fluorophores mentioned above can be used.

20 The following examples are offered by way of illustration and are not included to limit the invention in any manner. The examples show the procedures for synthesizing BODIPY®-tagged primers and performing DNA sequencing with said primers.

#### EXAMPLE 1

##### BODIPY® Fluorophores can Substitute for Conventional Sequencing Dyes

25 To examine the role of BODIPY® dyes in automated DNA sequencing, substitution experiments were performed by replacing a conventional dye with a corresponding BODIPY® dye having similar absorption/emission maxima. Different linker arms coupled to a universal sequencing primer were synthesized to chemically alter BODIPY® dye-

-35-

labeled primers to mimic the gel mobility pattern of conventional dye-labeled primers. Thus, BODIPY® dyes can replace one or more prior art dyes.

A. Reagents: DNA synthesis reagents were purchased from Applied Biosystems, Inc. (ABI) except 5'-amino-modifier C3, C6, and C12 phosphoramidites were purchased from Glen Research. Oligonucleotides R865, R932, R930, and R931 (Figure 2) were synthesized trityl-on (0.2 μmole scale) using either an ABI model 380B or model 394 DNA synthesizer and purified using Nensorb™ 20 columns according to the manufacturer's protocol (du Pont de Nemours & Co.). FAM-NHS, JOE-NHS, TAMRA-NHS, and ROX-NHS ester were purchased from ABI. 5-FAM-SE and BODIPY®-SE dyes were purchased from Molecular Probes and resuspended in anhydrous DMSO (50 mg/mL).

B. Preparation of fluorescent primers: Purified R865 primer (1.0 μmole) was resuspended in 240 μL of 0.5 M NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub> (pH 9.0) buffer and divided into eight aliquots. To each tube, 3 μL of either FAM-NHS ester, 5-FAM-SE, JOE-NHS ester, TAMRA-NHS ester, ROX-NHS ester, or 5 μL of BODIPY® 503/512-SE, BODIPY® 523/547-SE, BODIPY® 530/550-SE, BODIPY® 558/568-SE, BODIPY® 564/570-SE, BODIPY® 576/589-SE, BODIPY® 581/591-SE, or BODIPY® 589/616-SE, was added. Purified R930, R931, or R932 primers (0.6 μmole) were resuspended in 200 μL of 0.5 M NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub>, pH 9.0 buffer and divided into seven aliquots. To each tube, 5 μL of either BODIPY® 503/512-SE, BODIPY® 530/550-SE, BODIPY® 558/568-SE, BODIPY® 564/570-SE, BODIPY® 576/589-SE, BODIPY® 581/591-SE, or BODIPY® 589/616-SE, respectively was added. Reactions were incubated at 25°C for 16 h. Following ethanol precipitation, dye-labeled primers were purified by reverse-phase high performance liquid chromatography (RP-HPLC). Fluorescent primers

-36-

were resuspended in 10 mM Tris-HCl, pH 8.0 and 1mM EDTA and diluted to 0.4 pmol/ $\mu$ L.

C. RP-HPLC purification of oligonucleotides: The RP-HPLC hardware system used consists of a Beckman model 127 gradient solvent module, a 5 Rheodyne model 7125 injector, an Applied Biosystems (ABI) model 759A absorbance detector, and a Spectra-Physics model SP4600 DataJet integrator. Gradient RP-HPLC was performed using an ABI aquapore RP-300 column (4.6 mm  $\times$  250 mm) where "Buffer A" is 100 mM triethylammonium acetate (TEAA), pH 7.0, and "Buffer B" is 100 mM TEAA, 70% (v/v) acetonitrile. Dye-labeled oligonucleotides were purified 10 using the following gradient conditions: 20% Buffer B, 5 min.; 20% - 40% Buffer B, 30 min.; 40% - 100% Buffer B, 18 min.; 100% Buffer B, 5 min. at a flow rate of 1.0 mL per min.

D. Results: BODIPY<sup>®</sup> fluorophores can substitute for conventional 15 sequencing dyes or fluorophores. The chemical structures of different fluorophores and their corresponding absorption/emission maxima are shown in Figure 1. FAM, JOE, TAMRA, and ROX are four conventional fluorophores utilized in automated DNA sequencing. To examine the role of BODIPY<sup>®</sup> fluorophores in DNA sequencing, substitution experiments 20 were performed replacing conventional dye-labeled primers with BODIPY<sup>®</sup>s that correspond to the emission spectrum of the prior art, dye-labeled primers. Oligonucleotide R865, (Figure 2), was dye-labeled with the fluorophores listed in Figure 1 and purified by RP-HPLC. DNA sequencing reactions were generated by either solid-phase *Bst* sequencing 25 or Taq cycle-sequencing. The results of the substitution experiment are shown in Figure 3. Here, three dye-labeled termination products (i.e., FAM, TAMRA, and ROX) were generated, combined with either JOE or BODIPY<sup>®</sup> 530/550 termination products, and analyzed by automated DNA sequencing. With the exception of BODIPY<sup>®</sup> 589/616 reactions, BODIPY<sup>®</sup>

-37-

5 503/512-, BODIPY® 523/547-, BODIPY® 530/550-, BODIPY® 558/568-,  
BODIPY® 564/570-, BODIPY® 576/589-, and BODIPY® 581/591-labeled  
termination products migrated approximately 3/4 to 1 base pair faster  
through the gel than FAM-, JOE-, TAMRA-, or ROX-labeled termination  
products, respectively. The discrepancy between the two reactions is the  
result of the altered mobility of the different dye structures.

10 Although software modifications could have been employed to correct dye-primer mobility shifts, chemical modification of the R865 primer was performed (Figure 2). Oligonucleotides R930, R931, and R932 were dye-labeled with the BODIPY® dyes listed in Figure 1 and purified by RP-HPLC. As shown in Figure 3, increasing the linker arm length from (CH<sub>2</sub>)<sub>6</sub> to (CH<sub>2</sub>)<sub>12</sub> (R932) or addition of one 5' base plus (CH<sub>2</sub>)<sub>3</sub> (R930) or (CH<sub>2</sub>)<sub>6</sub> (R931) linker arm lengths slowed the mobility of BODIPY® 503/512-, BODIPY® 530/550-, and BODIPY® 564/570-labeled termination  
15 products. In fact, BODIPY® 503/512-R930, labeled termination reactions mimicked the spacing pattern of FAM-R865, BODIPY® 523/547-R931 and BODIPY® 530/550-R930 mimicked the spacing pattern of JOE-R865, BODIPY® 558/568-R930 and BODIPY® 564/570-R930 mimicked the spacing pattern of TAMRA-R865, and BODIPY® 576/589-R931, BODIPY® 581/591-R930, and BODIPY® 589/616-R865 mimicked the spacing pattern  
20 of ROX-R865, respectively, (compare highlighted boxes).

## EXAMPLE 2

### BODIPY® Dyes do not Require Differential Labeling or Software Correction for Discrepancies in Mobility

25 Additionally and particularly distinctively, the overwhelming majority of BODIPY® fluorophores alter the mobility of termination products *in the same way*, thus nullifying the need for chemical alteration of the fluorophore or software correction to generate accurate, evenly-spaced DNA sequences. Thus, due to their improved spectral qualities,

the use of BODIPY® fluorophores leads to improved DNA sequencing in general and, due to their effect (or lack of differential effect) on electrophoretic mobility, the use of BODIPY® fluorophores leads to improved automated DNA sequencing in particular.

5       **A. Reagents:** DNA synthesis reagents were purchased from Applied Biosystems, Inc. (ABI). Oligonucleotides were synthesized trityl-on (0.2 µmole scale) using either an ABI model 380B or model 394 DNA synthesizer and purified using Nensorb™ 20 columns according to the manufacturer's protocol (du Pont de Nemours & Co.). BODIPY® 523/547  
10      propionic acid (PA), and all BODIPY®-succinimidyl ester (SE) dyes were purchased from Molecular Probes. BODIPY®-SE dyes were resuspended in anhydrous DMSO (50 mg/mL), and BODIPY® 523/547-PA was converted to BODIPY® 523/547-SE according to the manufacturer's protocol.

15       **B. Preparation of fluorescent primers:** Purified R930 primers (0.4 µmole) was resuspended in 160 µL of 0.5 M NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub> (pH 9.0) buffer and divided into four aliquots. To each tube, 5 µL of BODIPY® 503/512-SE, BODIPY® 564/570-SE, or BODIPY® 581/591-SE was added. To the fourth tube, 35 µL of 0.25 M NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub>, pH 9.0 buffer and 30 µL BODIPY® 523/547-SE were added. Reactions were incubated at 25°C for 16 h.  
20      Following ethanol precipitation, dye-labeled primers were purified by reverse-phase high performance liquid chromatography (RP-HPLC). Fluorescent primers were resuspended in deionized (D.I.) water and diluted to 0.4 pmol/µL.

25       **C. RP-HPLC purification of oligonucleotides:** The RP-HPLC hardware system used consists of a Beckman model 127 gradient solvent module, a Rheodyne model 7125 injector, an Applied Biosystems (ABI) model 759A absorbance detector, and a Spectra-Physics model SP4600 DataJet integrator. Gradient RP-HPLC was performed using an ABI aquapore

-39-

RP-300 column (4.6 mm × 250 mm) where "Buffer A" is 100 mM triethylammonium acetate (TEAA), pH 7.0, and "Buffer B" is 100 mM TEAA, 70% (v/v) acetonitrile. Dye-labeled oligonucleotides were purified using the following gradient conditions: 20% Buffer B, 5 min.; 20% - 40%  
5 Buffer B, 30 min.; 40% - 100% Buffer B, 18 min.; 100% Buffer B, 5 min. at a flow rate of 1.0 mL per min.

D. Results: Different BODIPY® dyes do not alter significantly gel mobility. The striking observation that the same linker arm modification was required to substitute BODIPY® dyes for conventional dyes (see  
10 Example 1, above) led to the discovery that BODIPY® dyes could generate accurate, evenly-spaced DNA sequencing data without software correction for discrepancies in mobility. BODIPY® 503/512-"C", BODIPY® 530/550-"A", and BODIPY® 564/570-"G", and BODIPY® 581/591-"T" were chosen based on their chemical structure similarity. Figure 4 shows the  
15 comparison of DNA sequencing reads generated from four conventional dye-primers and four BODIPY® dye-primers using two different M13 clones. Figure 6 depicts the normalized emission spectra of four conventional dye-primers and BODIPY® dye-primers. It is important to note that all BODIPY® dyes were tethered to the primer via the tethers  
20 in Figure 2, and that no differential linker or nucleotide modification was required to achieve a precise, evenly-spaced, easily-read sequence reading.

### EXAMPLE 3

#### Method for BODIPY® Energy Transfer (BET) primers

To increase the emission intensity, doubly-labeled dye-primers were  
25 constructed and evaluated for fluorescence energy transfer (ET). To achieve efficient ET and maximal signal, oligonucleotides were systematically substituted with the acceptor dye at base increments away from either a FAM donor (0 to 3 bases apart) or a BODIPY® 503-512

donor (1 to 6 bases apart). It was observed that ET efficiency decreased with increasing distance, and decreased with decreasing spectral overlap between donor and acceptor dyes.

**A. Reagents:** DNA synthesis reagents were purchased from ABI except

5 5'-amino-modifier C3, C6, and C12, and amino modifier C6 dT phosphoramidites were purchased from Glen Research. Oligonucleotides FET and BET primers were synthesized trityl-on, using either an ABI model 380B or model 394 DNA synthesizer. BODIPY® 523/547 propionic acid (PA), and all BODIPY®-SE dyes were purchased from Molecular  
10 Probes. BODIPY®-SE dye were resuspended in anhydrous DMSO (50 mg/mL), and BODIPY® 523/547-PA was converted to BODIPY® 523/547-SE according to the manufacturer's protocol.

**B. Fluorescent primers:** The donor dye for the FET-3 primer

(5'-FAM-T'GTAAAACGACGGCCAGT was synthesized (0.2  $\mu$ mole) using

15 6-FAM amidite and C6dT (T') and was ethanol precipitated. The donor dye for the BET-3 primer (5'-NTT'GTAAAACGACGGCCAGT, was synthesized (0.2  $\mu$ mole) using either C3 or C6 amino link (N) and C6dT (T') and resuspended in 200  $\mu$ L of 0.1 N NaOH. To BET-3 primer, 10  $\mu$ L of BODIPY® 503/512-SE was added, incubated at 25 °C for 10 min., ethanol  
20 precipitated, incubated in 200  $\mu$ L of 80% acetic acid for 20 min., and ethanol precipitated. Both FET-3 and BET-3 primers were each resuspended in 160  $\mu$ L of 0.25 M NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub>, pH 9.0 buffer and divided into four aliquots. To three tubes, 3  $\mu$ L of either BODIPY® 503/512-SE, BODIPY® 564/570-SE, or BODIPY® 581/591-SE, respectively  
25 was added. To the fourth tube, 35  $\mu$ L of 0.25 M NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub>, pH 9.0 buffer and 30  $\mu$ L BODIPY® 523/547-SE were added. All dye labeling reactions were incubated at 25 °C for 16 h. Following ethanol precipitation, dye-labeled primers were purified by RP-HPLC, resuspended in 10 mM Tris-HCl, pH 8.0 and 1mMEDTA, and diluted to 0.4 pmol/ $\mu$ L.

-41-

C. RP-HPLC: The RP-HPLC hardware system consisted of a Beckman model 127 gradient solvent module, a Rheodyne model 7125 injector, an Applied Biosystems (ABI) model 759A absorbance detector, and a Spectra-Physics model SP4600 DataJet integrator. Gradient RP-HPLC was performed using an ABI aquapore RP-300 column (4.6 mm X 250 mm) where "Buffer A" is 100 mM triethylammonium acetate (TEAA), pH 7.0 and "Buffer B" is 100 mM TEAA, 70 % (v/v) acetonitrile. Dye-labeled oligonucleotides were purified using the following gradient conditions: 20% B, 5 min.; 20% B - 40% B, 30 min.; 40% B - 100% B, 18 min.; 100% B, 5 min. at a flow rate of 1.0 mL per min.

D. Results: A three base separation between either the FAM donor (FET-3) or the BODIPY<sup>®</sup> 503-512 donor (BET-3) (Figure 2B), and acceptor dyes was observed to give the greatest signal enhancement for BODIPY<sup>®</sup> 564/570 and BODIPY<sup>®</sup> 581/591 dyes, consistent with FAM-TAMRA and FAM-ROX dye pairs. However, BET-3 dye primers showed considerably greater ET efficiencies and signal enhancements over FET-3 dye primers.

See Table 1.

TABLE 1

Acceptor dyes	Signal enhancements		ET efficiencies	
	BET-3	FET-3	BET-3	FET-3
BODIPY® 503/512	154%	80%		
BODIPY® 523/547	91%	35%	99%	93%
BODIPY® 564/570	360%	200%	99%	92%
BODIPY® 581/591	540%	470%	98%	67%

5

For BODIPY® 503/512 and BODIPY® 523/547 acceptor dyes, BET-3 dye-primers showed approximately the same signal strength compared to their single dye counterpart, but significant signal loss was observed for the FET-3 dye primers. Comparison of the normalized, overlapping spectral profiles of BET-3 dye-primers was indistinguishable from the single BODIPY® dye-primer spectra shown in Figure 3, consistent with efficient ET. Overall, the strong signal enhancement of the weaker fluorescent dyes contrasted with minimal enhancements of the normally stronger fluorescent dyes to produce a four dye-primer set with roughly balanced signal intensities.

10

The sensitivity of the complete BET-3 primer set was examined by serial dilutions of DNA template using an ABI 377A DNA sequencer on a single gel and sufficient signal was correctly analyzed even with a sixteen-fold reduction. This increased sensitivity of BET-3 dye-primers enables the direct loading of sequencing reactions onto gels without a previously-required laborious concentration step.

15

The unprocessed fluorescent signals generated from BET-3 sequencing reactions demonstrates the benefits of the uniform mobility, properly-balanced signal outputs and improved spectral purity of the

25

-43-

present method. The raw data from BET-3 reactions generates a DNA sequencing pattern that is visually interpretable and agrees well with the corresponding analyzed data. In contrast, no discernable sequence pattern could be detected from the unprocessed signals of conventional primers.

5      **Figure 4.**

**EXAMPLE 4**  
**Method for Phosphoramidite Labeling**

10      **A. Reagents:** 6-Aminohexanol, 2-cyanoethyl *N,N*-diisopropylchlorophosphoramidite, *N,N*-diisopropylethylamine, and all solvents were purchased from Aldrich. Amine-VN-phosphoramidite was purchased from CLONTECH. BODIPY®-SE dyes were purchased from Molecular Probes and resuspended in anhydrous DMSO (50 mg/mL). FAM-NHS was purchased from ABI.

15      **B. Synthesis:** The general synthesis for two different schemes (route I and II) is outlined in **Figure 5.**

20      Route I: Compound [I]: 6-amino hexanol (1 g, 8.5 mmol) is dried by co-evaporation with pyridine (2 X 10 mL; HPLC grade) under reduced pressure. Residual pyridine is removed by evacuation at 0.1 mm Hg for 2 hours. The solid in methylene chloride (20 mL) is dissolved, and while stirring, freshly distilled diisopropylethylamine (3 mL, 17 mmol) is added. To the solution, a solution of BODIPY®-SE (8.5 mmol) in methylene chloride (10 mL) is added through a dropping funnel under an inert atmosphere. After 30 min of stirring, the progress of the reaction is monitored by thin layer chromatography (TLC). The reaction is usually complete in 1 hour. When the reaction is complete, the reaction mixture is washed with 5% NaHCO<sub>3</sub> solution (3 X 15 mL), followed by saturated NaCl solution (15 mL). After drying the methylene chloride solution over

anhydrous Na<sub>2</sub>SO<sub>4</sub>, the solvent is evaporated on a rotary evaporator to a yellow oil.

Route I: Compound [II]: Dye-labeled hexanol (6 mmol) is dried under high vacuum for 3 hours and dissolved in freshly distilled THF (from sodium metal and benzophenone, 10 mL). Diisopropylethylamine (1 mL, 6 mmol) is added and the solution is stirred at 0°C for 10 minutes. 2-cyanoethyl N,N-diisopropylchloro-phosphoramidite (1.7 mL, 7.5 mmol) is added dropwise through a syringe under an argon atmosphere. The amine hydrochloride should precipitate within 5 minutes of addition. The mixture should be stirred for 30 minutes at 0°C and then stirred at room temperature for 1 hour. The progress of the reaction is monitored by TLC. When the reaction is complete, the amine hydrochloride is removed by filtering through a sintered glass funnel under argon and the solid is washed with dry THF (2 X 10 mL). The combined filtrate is evaporated to a viscous oil on a rotary evaporator. The viscous oil is then dissolved in argon-purged ethyl acetate and the solution is washed with ice-cold 5% aqueous NaHCO<sub>3</sub> solution (2 X 10 mL) followed by saturated NaCl (10 mL). The ethyl acetate solution is dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate is concentrated to a yellow oil on a rotary evaporator.

Route II: Compounds [III] and [IV]: 2'-deoxyribosyl moiety [III] (Smith et al., 1994) is dissolved in piperidine, DMF. To this solution, a solution of BODIPY®-SE (8.5 mmol) in DMF (10 mL) is added under an inert atmosphere. Diisopropylethylamine (1 mL, 6 mmol) is added and the solution is stirred at 0°C for 10 minutes. 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (1.7 mL, 7.5 mmol) is then added dropwise through a syringe under an argon atmosphere. The amine hydrochloride should precipitate within 5 minutes. This mixture is then stirred for 30 minutes at 0°C and at room temperature for 1 hour. The progress of the reaction is monitored by TLC. When the reaction is complete, amine hydrochloride is removed by filtering through a sintered glass funnel under argon and the solid is washed with dry THF (2 X 10

mL). The combined filtrate is evaporated to a viscous oil on a rotary evaporator and the viscous oil is then dissolved in argon-purged ethyl acetate and washed with ice-cold 5% aqueous NaHCO<sub>3</sub> solution (2 X 10 mL), followed by saturated NaCl (10 mL). The ethyl acetate solution is  
5 then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to a yellow oil on a evaporate rotary evaporator.

C. Purification: Route I: Compound [I]: A glass column is packed with 100 g silica gel-60 using a mixture of methanol: ethyl acetate: methylene chloride: (0.5:6.0:93.5 v/v/v) containing 1% pyridine. The yellow oil is  
10 dissolved in 10 mL of the above solvent mixture and the solution is loaded onto the column. A mixture of methanol ethyl acetate: dichloromethane (1:12:87 v/v/v) is used to elute the column and fractions are collected. Each fraction is checked for absorbance at the absorption wavelength  
15 maximum of the BODIPY® dye. Pooled fractions are then evaporated on a rotary evaporator and the residue is dried to constant weight on high vacuum.

Route I: Compound [II]: A glass column is packed with 50 g silica gel-60 using a mixture of methanol: ethyl acetate: methylene chloride: (0.5:6.0:93.5 v/v/v) containing 1% pyridine. The silica column is washed  
20 with a one-column volume of 25% ethyl acetate in hexane. The sample is dissolved in a minimum volume of 50% ethyl acetate in hexane and loaded onto the column. The column is then eluted with 25% ethyl acetate in hexane and fractions are collected. The fractions are monitored by TLC (50% ethyl acetate in hexane). The product is detected by shortwave UV,  
25 and the desired fractions are combined and concentrated under reduced pressure using a rotary evaporator.

Route II: Compounds [III] and [IV]: A glass column is packed with 50 g silica gel-60 using a mixture of methanol: ethyl acetate: methylene chloride: (0.5:6.0:93.5 v/v/v) containing 1% pyridine. The silica column is  
30 washed with one column volume of 25% ethyl acetate in hexane. The

-46-

sample is then dissolved in a minimum volume of 50% ethyl acetate in hexane and loaded onto the column. The column is eluted with 25% ethyl acetate in hexane and fractions are collected. The fractions are monitored by TLC (50% ethyl acetate in hexane). The product is detected by  
5 shortwave UV. The desired fractions are collected and concentrated under reduced pressure using a rotary evaporator.

**EXAMPLE 5**  
**Method for labelling AP-3 nucleotides**

A. Reagents: AP-3 nucleotides were purchased from DuPont NEN  
10 Products and dissolved and diluted to a final concentration of 10 mM. All BODIPY®-SE dyes were purchased from Molecular Probes and were resuspended in anhydrous DMSO (50 mg/mL).

B. Fluorescent terminators: To AP-3 ribonucleotides, deoxyribonucleotides or dideoxynucleotides (0.1 μmole), 30 μL of 0.25 M  
15 NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub>, pH 9.0 buffer was added followed by the addition of 5 μL of BODIPY-SE dyes. All dye labelling reactions were incubated at 25°C for 16 h. Dye-labeled nucleotides were purified by RP-HPLC, evaporated to near dryness and diluted in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA.

C. RP-HPLC: The RP-HPLC hardware system consisted of a Beckman model 127 gradient solvent module, A Rheodyne model 7125 injector, an Applied Biosystems (ABI) model 759A absorbance detector, and a Spectra-Physics model SP4600 DataJet integrator. Gradient RP-HPLC was performed using an ABI aquapore OD-300 column (4.6 mm X  
25 250 mm) where "Buffer A" is 100 mM triethylammonium acetate (TEAA), pH 7.0 and "Buffer B" is 100 mM TEAA, 70% (v/V) acetonitrile. Dye-labeled ribonucleotides, deoxynucleotides or dideoxynucleotides were

-47-

purified using the following gradient conditions: 0% B, 5 minutes; 0% B - 40% B, 30 minutes; 40% B - 100% B, 18 minutes; 100% B, 5 minutes at a flow rate of 1.0 mL per minute.

#### EXAMPLE 6

5

#### Labelled DNA for Taqman Assay

A. Reagents: DNA synthesis reagents were purchased from ABI except 5'-amino-modifier C3, C6, and C12 and amino modifier C6 dT phosphoramidites and 3'-amino-modifier CPG were purchased from Glen Research. Oligonucleotides BET primers were synthesized on 3'-amino-modifier CPG column trityl-on, auto-cleavage using either an BI model 380B or model 394 DNA synthesizer. All BODIPY-SE dyes were purchased from Molecular Probes. BODIPY-SE dye were resuspended in anhydrous DMSO (50 mg/mL).

B. Fluorescent primers: The leader sequences for BET dye-primers are 5'-NTGTT\* or 5'-NACGTTGT\* followed by any primer sequence that is completely complementary to the target sequence. Primers were synthesized (0.2  $\mu$ mole) using either C3 or C6 amino link (N) and C6dT (T\*) and resuspended in 400  $\mu$ l of 0.01 N NaOH. To each tube, 10  $\mu$ l of BODIPY 503/512-SE, BODIPY 523/547 or BODIPY 530/550 was added, incubated at 25°C for 10 min., ethanol precipitated, incubated in 200  $\mu$ l of 80% acetic acid for 20 min., and ethanol precipitated. BODIPY primers were resuspended in 200  $\mu$ L of 0.25 M NaHCO<sub>3</sub>/Na<sub>2</sub>CO<sub>3</sub>, pH 9.0 buffer and 10  $\mu$ L of either BODIPY 588/568-SE, BODIPY 564/570-SE, BODIPY 576/589-SE, BODIPY 581/591-SE, or BODIPY 589/616-SE, was added and the mixtures were incubated at 25°C for 16 h. Following ethanol precipitation, dye-labeled primers were purified by RP-HPLC, resuspended in deionized (DI) water, and diluted to 0.4 pmol/ $\mu$ l.

C. RP-HPLC. The RP-HPLC hardware system consisted of a Beckman model 127 gradient solvent module, a Rheodyne model 7125 injector, an Applied Biosystems (ABI) model 759A absorbance detector, and a Spectra-Physics model SP4600 DataJet integrator. Gradient RP-HPLC was performed using an ABI aquapore RP-300 column (4.6 mm X 250 mm) where "Buffer A" is 100 mM triethylammonium acetate (TEAA), pH 7.0 and "Buffer B" is 100mM TEAA 70% (v/v) acetonitrile. Dye-labeled oligonucleotides were purified using the following gradient conditions: 5 20% B, 5 minutes; 20% B-40% B, 30 minutes; 40% B- 100% B, 18 minutes; 10 100% B, 5 minutes at a flow rate of 1.0 ml per minute.

One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The oligonucleotides, dyes, methods, procedures and techniques described herein are presently representative of the preferred embodiments, are intended to be exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, and are encompassed within the spirit of the invention or defined by the scope of the appended claims. All references specifically cited herein are incorporated by reference. 15 20

## WE CLAIM:

1        1. A method for DNA sequencing wherein polynucleotide products of  
2        said DNA sequencing are 5'-end-labelled with substituted 4,4-difluoro-4-  
3        bora-3A,4A-diaza-s-indacene (BODIPY® fluorophore).

1        2. A method for distinguishing polynucleotides having different 3'-  
2        terminal dideoxynucleotides in any method of DNA sequencing requiring  
3        electrophoresis of products of the sequencing reactions, the method  
4        comprising the steps of:

5               forming a mixture of a first, a second, a third, and a fourth  
6        class of polynucleotides, each polynucleotide in the first class  
7        having a 3'-terminal dideoxyadenosine and being labeled at a 5'  
8        position with a first fluorophore; each polynucleotide in the second  
9        class having a 3'-terminal dideoxycytidine and being labeled at a 5'  
10      position with a second fluorophore; each polynucleotide in the third  
11      class having a 3'-terminal dideoxyguanosine and being labeled at  
12      a 5' position with a third fluorophore; and each polynucleotide in  
13      the fourth class having a 3'-terminal dideoxythymidine and being  
14      labeled at a 5' position with a fourth fluorophore; wherein at least  
15      one of said fluorophores is a BODIPY® fluorophore, and, wherein  
16      if said first, second, third and fourth fluorophores are all different,  
17      said polynucleotides can be electrophoresed in a same or a different  
18      lane, and wherein if any of said first, second, third or fourth  
19      fluorophores are the same, said polynucleotides labeled with said  
20      same fluorophores are electrophoresed in separate lanes;

21               electrophoretically separating on a gel by size the  
22      polynucleotides; illuminating with an illumination beam the bands on the  
23      gel, the illumination beam being capable of causing the fluorophores to  
24      fluoresce; and

-50-

25 identifying the classes of polynucleotides in the bands by the  
26 fluorescence or absorption spectrum of the fluorophores.

1 3. A method for distinguishing polynucleotides having different 3'-  
2 terminal dideoxynucleotides in the chain termination method of DNA  
3 sequencing, the method comprising the steps of:

4 forming a mixture of a first, a second, a third, and a fourth  
5 class of polynucleotides, each polynucleotide in the first class  
6 having a 3'-terminal dideoxyadenosine and being labeled at a 5'  
7 position with BODIPY® 523/547, BODIPY® 530/550 or JOE; each  
8 polynucleotide in the second class having a 3'-terminal  
9 dideoxycytidine and being labeled at a 5' position with BODIPY®  
10 503/512 or FAM; each polynucleotide in the third class having a 3'-  
11 terminal dideoxyguanosine and being labeled at a 5' position with  
12 BODIPY® 558/568, BODIPY® 564/570 or TAMRA; and each  
13 polynucleotide in the fourth class having a 3'-terminal  
14 dideoxythymidine and being labeled at a 5' position with BODIPY®  
15 576/589, BODIPY® 581/591, BODIPY® 589/616, or ROX; wherein  
16 at least one of said classes is labeled with a BODIPY® fluorophore;

17 electrophoretically separating on a gel by size the  
18 polynucleotides; illuminating with an illumination beam the bands  
19 on the gel, the illumination beam being capable of causing the  
20 fluorophores to fluoresce; and

21 identifying the classes of polynucleotides in the bands by the  
22 fluorescence or absorption spectrum of the fluorophores.

1 4. A method for distinguishing polynucleotides having different 3'-  
2 terminal dideoxynucleotides in the chain termination method of DNA  
3 sequencing, the method comprising the steps of:

4 forming a mixture of a first, a second, a third, and a fourth  
5 class of polynucleotides, each polynucleotide in the first class

-51-

6 having a 3'-terminal dideoxyadenosine and being labeled at a 5'  
7 position with a first BODIPY® fluorophore; each polynucleotide in  
8 the second class having a 3'-terminal dideoxycytidine and being  
9 labeled at a 5' position with a second BODIPY® fluorophore; each  
10 polynucleotide in the third class having a 3'-terminal  
11 dideoxyguanosine and being labeled at a 5' position with a third  
12 BODIPY® fluorophore; and each polynucleotide in the fourth class  
13 having a 3'-terminal dideoxythymidine and being labeled at a 5'  
14 position with a fourth BODIPY® fluorophore; wherein said first,  
15 second, third and fourth BODIPY® fluorophore are all different;  
16 electrophoretically separating on a gel by size the  
17 polynucleotides;

18 illuminating with an illumination beam bands of said gel,  
19 said illumination beam being capable of causing said BODIPY®  
20 fluorophores to fluoresce; and

21 identifying the classes of polynucleotides in the bands by the  
22 fluorescence or absorption spectrum of the dyes.

1 5. The method of claims 1, 2, 3, or 4, wherein said BODIPY®  
2 fluorophores have an adsorption maxima of about 450 to 700, and an  
3 emission maxima of about 450 to 700.

1 6. The method of claims 1, 2, 3, or 4, wherein said BODIPY®  
2 fluorophores have adsorption maxima of about 480 to 650, and an  
3 emission maxima of about 480 to 650.

1 7. The method of claims 2, 3, or 4, wherein said chain termination  
2 method of DNA sequencing is performed by an automated DNA  
3 sequencing instrument.

-52-

1       8. The method of claims 2, 3, or 4, further including the step of  
2 extending from a primer a plurality of polynucleotides by means of a DNA  
3 polymerase or a reverse transcriptase in the presence of dideoxyadenosine  
4 triphosphate, dideoxycytosine triphosphate, dideoxyguanosine  
5 triphosphate, and dideoxythymidine triphosphate to form said first,  
6 second, third, and fourth classes of polynucleotides.

1       9. The method of claim 8, wherein said DNA polymerase is selected  
2 from the group of Thermosequenase, Klenow fragment, Sequenase®, *Bst*  
3 DNA polymerase, AmpliTaq® DNA polymerase, *Pfu*(exo-)DNA polymerase,  
4 *rTth* DNA polymerase or Vent(exo-) DNA polymerase, and the reverse  
5 transcriptase is selected from the group of AMV-RT or M-MuLV-RT.

1       10. The methods of claim 1, 2, 3, or 4, wherein said BODIPY®  
2 fluorophores are coupled to a primer suitable for sequencing by a linker.

1       11. The method of claim 10, wherein said linker has the formula  $(CH_2)_n$ ,  
2 where  $n = 1 - 30$ .

1       12. The method of claim 11, wherein said linkers are selected from the  
2 group of  $(CH_2)_3$ ,  $(CH_2)_8$ , and  $(CH_2)_{12}$ .

1       13. The method of claim 1, 2, 3, or 4, wherein said BODIPY®  
2 fluorophore is attached at the 5' end of the products of the sequencing  
3 reaction and an additional fluorophore is attached at a 3' position of the  
4 product of the sequencing reaction or at one or more internal positions of  
5 the products of the sequencing reaction.

1       14. The method of claim 13, wherein said additional fluorophore is a  
2 BODIPY® fluorophore.

-53-

1       15. The method of claim 13, wherein said additional fluorophore is FAM.

1       16. The method of claim 14, wherein said additional fluorophore has an  
2       adsorption maxima of about 475 to 650.

1       17. The method of claim 16 wherein said additional fluorophore is  
2       BODIPY® 523/547.

1       18. The method of claim 16, wherein said additional fluorophore is  
2       BODIPY® 503/512.

1       19. A method for distinguishing polynucleotide sequences in a  
2       hybridization method of DNA sequencing, said method comprising the  
3       steps of:

4             synthesizing a first, a second, a third and a fourth class of  
5       oligonucleotides, wherein all of said classes of oligonucleotides have  
6       a same length, said first, second, third and fourth classes of  
7       oligonucleotides differ from the oligonucleotides of each other class  
8       by one nucleotide base at a 3', a 5' or an internal position, and  
9       each oligonucleotide of the first class has a deoxyadenosine at said  
10      position and is labeled at a 5' position with a first fluorophore;  
11      each oligonucleotide in the second class has a deoxycytidine at said  
12      position and is labeled at a 5' position with a second fluorophore;  
13      each oligonucleotide in the third class having a deoxyguanosine at  
14      said position and is labeled at a 5' position with a third  
15      fluorophore; and each oligonucleotide in the fourth class has a  
16      deoxythymidine at said position and is labeled at a 5' position with  
17      a fourth fluorophore; wherein at least one of said fluorophores is a  
18      BODIPY® fluorophore;

19 hybridizing said oligonucleotides to a single-stranded DNA  
20 target immobilized to a solid support, wherein said solid support is  
21 in a grid format, to form a hybridized product;

22 washing said hybridized product to remove any unhybridized  
23 oligonucleotide or target;

24 illuminating with an illumination beam the solid support,  
25 said illumination beam being capable of causing said BODIPY®  
26 fluorophores to fluoresce; and

27 identifying the classes of polynucleotides in the bands by the  
28 fluorescence or absorption spectrum of the dyes.

1 20. The method of claim 19 wherein said at least one BODIPY®  
2 fluorophore has an adsorption maxima of about 450 to 700, and an  
3 emission maxima of about 450 to 700.

1 21. The method of claim 20, wherein said at least one BODIPY®  
2 fluorophore has adsorption maxima of about 480 to 650, and an emission  
3 maxima of about 480 to 650.

1 22. A method for genetic analysis of DNA fragments wherein said DNA  
2 fragments are labelled at a 5' position with at least one BODIPY®  
3 fluorophore.

1 23. A method for distinguishing polynucleotides having different 3'-  
2 terminal dideoxynucleotides in the chain termination method of DNA  
3 sequencing, the method comprising the steps of:

4 forming a mixture of a first, a second, a third, and a fourth  
5 class of polynucleotides, each polynucleotide in the first class  
6 having a 3'-terminal dideoxyadenosine and being labeled at a 5'  
7 position with BODIPY® 523/547; each polynucleotide in the second  
8 class having a 3'-terminal dideoxycytidine and being labeled at a 5'

9 position with BODIPY® 503/512; each polynucleotide in the third  
10 class having a 3'-terminal dideoxyguanosine and being labeled at  
11 a 5' position with BODIPY® 564/570; and each polynucleotide in  
12 the fourth class having a 3'-terminal dideoxythymidine and being  
13 labeled at a 5' position with BODIPY® 581/591; wherein at least  
14 one of said classes is labeled with a BODIPY® fluorophore;

15 electrophoretically separating on a gel by size the  
16 polynucleotides; illuminating with an illumination beam the bands  
17 on the gel, the illumination beam being capable of causing the  
18 fluorophores to fluoresce; and

19 identifying the classes of polynucleotides in the bands by the  
20 fluorescence or absorption spectrum of the fluorophores.

1 24. A method for distinguishing polynucleotides having different 3'-  
2 terminal dideoxynucleotides in the chain termination method of DNA  
3 sequencing, the method comprising the steps of:

4 forming a mixture of a first, a second, a third, and a fourth  
5 class of polynucleotides, each polynucleotide in the first class  
6 having a 3'-terminal dideoxyadenosine and being labeled at a 5'  
7 position with BODIPY® 523/547; each polynucleotide in the second  
8 class having a 3'-terminal dideoxycytidine and being labeled at a 5'  
9 position with BODIPY® 581/591; each polynucleotide in the third  
10 class having a 3'-terminal dideoxyguanosine and being labeled at  
11 a 5' position with BODIPY® 503/512; and each polynucleotide in  
12 the fourth class having a 3'-terminal dideoxythymidine and being  
13 labeled at a 5' position with BODIPY® 564/570; wherein at least  
14 one of said classes is labeled with a BODIPY® fluorophore;

15 electrophoretically separating on a gel by size the  
16 polynucleotides; illuminating with an illumination beam the  
17 bands on the gel, the illumination beam being capable of causing  
18 the fluorophores to fluoresce; and

19 identifying the classes of polynucleotides in the bands by the  
20 fluorescence or absorption spectrum of the fluorophores.

1 25. A method for distinguishing polynucleotides having different 3'-  
2 terminal dideoxynucleotides in any method of chain termination DNA  
3 sequencing, said method comprising the steps of:

4 forming a mixture of a first, a second, a third, and a fourth class of  
5 polynucleotides, each polynucleotide in the first class having a 3'-terminal  
6 dideoxyadenosine triphosphate, said 3'-terminal dideoxyadenosine  
7 triphosphate being attached at the 7 position of the 7-deazapurine to a 3-  
8 amino-1-propynyl linker, said linker then attached to a BODIPY® linker  
9 at a 3 position of a first BODIPY® fluorophore that contains at least one  
10 reactive functional group; each polynucleotide in the second class having  
11 a 3'-terminal dideoxycytidine triphosphate, said 3'-terminal  
12 dideoxycytidine triphosphate being attached at the 5 position of the  
13 pyrimidine to a 3-amino-1-propynyl linker, said linker then attached to a  
14 BODIPY® linker at a 3 position of a second BODIPY® fluorophore that  
15 contains at least one reactive functional group; each polynucleotide in the  
16 third class having a 3'-terminal dideoxyguanosine triphosphate, said 3'-  
17 terminal dideoxyguanosine triphosphate being attached at the 7 position  
18 of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then  
19 attached to a BODIPY® linker at a 3 position of a third BODIPY®  
20 fluorophore that contains at least one reactive functional group; each  
21 polynucleotide in the fourth class having a 3'-terminal dideoxythymidine  
22 triphosphate, said 3'-terminal dideoxythymidine triphosphate being  
23 attached at the 5 position of the pyrimidine to a 3-amino-1-propynyl  
24 linker, said linker then attached to a BODIPY® linker at a 3 position of  
25 a fourth BODIPY® fluorophore that contains at least one reactive  
26 functional group; wherein if said first, second, third and fourth BODIPY®  
27 fluorophores are all different, said polynucleotides can be electrophoresed  
28 in a same or a different lane; or wherein if any of said first, second, third

29 or fourth fluorophores are the same, said polynucleotides labeled with said  
30 same fluorophores are electrophoresed in separate lanes;

31       electrophoretically separating on a gel by size the polynucleotides;  
32       illuminating with an illumination beam the bands on the gel, the  
33       illumination beam being capable of causing the fluorophores to fluoresce;  
34       and

35       identifying the classes of polynucleotides in the bands by the  
36       fluorescence or absorption spectrum of the fluorophores.

1       26. The method of claim 25, wherein the BODIPY® fluorophores are  
2       selected from the group of BODIPY® 530/550; BODIPY® 503/512;  
3       BODIPY® 564/570; BODIPY® 589/616; BODIPY® 581/591; BODIPY®  
4       523/547; BODIPY® 558/568; and BODIPY® 576/589.

1       27. The method of claim 25, wherein said 3'-terminal dideoxyadenosine  
2       triphosphate is labeled with BODIPY® 523/547 or BODIPY® 530/550; said  
3       3'-terminal dideoxycytidine triphosphate is labeled with BODIPY®  
4       576/589, BODIPY® 581/591, or BODIPY® 589/616; said 3'-terminal  
5       dideoxyguanosine triphosphate is labeled with BODIPY® 503/512; and said  
6       3'-terminal dideoxythymidine triphosphate is labeled with BODIPY®  
7       558/568 or BODIPY® 564/570.

1       28. The method of claim 25, wherein said BODIPY® fluorophores have  
2       an adsorption maxima of about 450 to 700, and an emission maxima of  
3       about 450 to 700.

1       29. The method of claim 25, wherein said chain termination method of  
2       DNA sequencing is performed by an automated DNA sequencing  
3       instrument.

1       30. The method of claim 25, wherein said classes of polynucleotides are  
2       formed using a DNA polymerase selected from the group of Klenow  
3       fragment, Sequenase®, *Bst* DNA polymerase, AmpliTaq® DNA polymerase,  
4       *Pfu*(exo-)DNA polymerase, Thermosequenase®, *rTth* DNA polymerase or  
5       Vent(exo-) DNA polymerase, and the reverse transcriptase is selected from  
6       the group of AMV-RT or M-MuLV-RT.

1       31. A method for distinguishing polynucleotides having different  
2       ribonucleotides in any method of labelling polynucleotides by enzymatic  
3       incorporation, said method comprising the steps of:

4              forming a mixture of a first, a second, a third, and a fourth class of  
5       polynucleotides, each polynucleotide in the first class having an adenosine  
6       triphosphate, said adenosine triphosphate being attached at the 7 position  
7       of the 7-deazapurine to a 3-amino-1-propynyl linker, said linker then  
8       attached to a BODIPY® linker at a 3 position of a first BODIPY®  
9       fluorophore that contains at least one reactive functional group; each  
10      polynucleotide in the second class having a cytidine triphosphate, said  
11      cytidine triphosphate being attached at the 5 position of the pyrimidine  
12      to a 3-amino-1-propynyl linker, said linker then attached to a BODIPY®  
13      linker at a 3 position of a second BODIPY® fluorophore that contains at  
14      least one reactive functional group; each polynucleotide in the third class  
15      having a guanosine triphosphate, said guanosine triphosphate being  
16      attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl  
17      linker, said linker then attached to a BODIPY® linker at a 3 position of  
18      a third BODIPY® fluorophore that contains at least one reactive  
19      functional group; each polynucleotide in the fourth class having a uracil  
20      triphosphate, said uracil triphosphate being attached at the 5 position of  
21      the pyrimidine to a 3-amino-1-propynyl linker, said linker then attached  
22      to a BODIPY® linker at a 3 position of a fourth BODIPY® fluorophore  
23      that contains at least one reactive functional group; wherein if said first,  
24      second, third and fourth BODIPY® fluorophores are all different, said

25 polynucleotides can be electrophoresed in a same or a different lane; or  
26 wherein if any of said first, second, third or fourth fluorophores are the  
27 same, said polynucleotides labeled with said same fluorophores are  
28 electrophoresed in separate lanes;

29       electrophoretically separating on a gel by size the polynucleotides;  
30       illuminating with an illumination beam the bands on the gel, the  
31       illumination beam being capable of causing the fluorophores to fluoresce;  
32       and

33       identifying the classes of polynucleotides in the bands by the  
34       fluorescence or absorption spectrum of the fluorophores.

1       32. The method of claim 31, wherein the BODIPY® fluorophores are  
2       selected from the group of BODIPY® 530/550; BODIPY® 503/512;  
3       BODIPY® 564/570; BODIPY® 589/616; BODIPY® 581/591; BODIPY®  
4       523/547; BODIPY® 558/568; and BODIPY® 576/589.

1       33. The method of claim 31, wherein said adenosine triphosphate is  
2       labeled with BODIPY® 523/547 or BODIPY® 530/550; said cytidine  
3       triphosphate is labeled with BODIPY® 576/589, BODIPY® 581/591, or  
4       BODIPY® 589/616; said guanosine triphosphate is labeled with BODIPY®  
5       503/512; and said uracil triphosphate is labeled with BODIPY® 558/568 or  
6       BODIPY® 564/570.

1       34. The method of claim 31, wherein said BODIPY® fluorophores have  
2       an adsorption maxima of about 450 to 700, and an emission maxima of  
3       about 450 to 700.

1       35. The method of claim 31, wherein said internal labelling and  
2       distinguishing polynucleotides is performed by an automated  
3       GeneScanner.

-60-

1       36. A method for distinguishing polynucleotides having different  
2       deoxyribonucleotides in any method of labelling polynucleotides by  
3       enzymatic incorporation, said method comprising the steps of:

4              forming a mixture of a first, a second, a third, and a fourth class of  
5       polynucleotides, each polynucleotide in the first class having a  
6       deoxyadenosine triphosphate, said deoxyadenosine triphosphate being  
7       attached at the 7 position of the 7-deazapurine to a 3-amino-1-propynyl  
8       linker, said linker then attached to a BODIPY® linker at a 3 position of  
9       a first BODIPY® fluorophore that contains at least one reactive functional  
10      group; each polynucleotide in the second class having a deoxycytidine  
11      triphosphate, said deoxycytidine triphosphate being attached at the 5  
12      position of the pyrimidine to a 3-amino-1-propynyl linker, said linker then  
13      attached to a BODIPY® linker at a 3 position of a second BODIPY®  
14      fluorophore that contains at least one reactive functional group; each  
15      polynucleotide in the third class having a deoxyguanosine triphosphate,  
16      said deoxyguanosine triphosphate being attached at the 7 position of the  
17      7-deazapurine to a 3-amino-1-propynyl linker, said linker then attached to  
18      a BODIPY® linker at a 3 position of a third BODIPY® fluorophore that  
19      contains at least one reactive functional group; each polynucleotide in the  
20      fourth class having a deoxythymidine triphosphate, said deoxythymidine  
21      triphosphate being attached at the 5 position of the pyrimidine to a 3-  
22      amino-1-propynyl linker, said linker then attached to a BODIPY® linker  
23      at a 3 position of a fourth BODIPY® fluorophore that contains at least one  
24      reactive functional group; wherein if said first, second, third and fourth  
25      BODIPY® fluorophores are all different, said polynucleotides can be  
26      electrophoresed in a same or a different lane; or wherein if any of said  
27      first, second, third or fourth fluorophores are the same, said  
28      polynucleotides labeled with said same fluorophores are electrophoresed  
29      in separate lanes;

30              electrophoretically separating on a gel by size the polynucleotides;

-61-

31        illuminating with an illumination beam the bands on the gel, the  
32        illumination beam being capable of causing the fluorophores to fluoresce;  
33        and

34        identifying the classes of polynucleotides in the bands by the  
35        fluorescence or absorption spectrum of the fluorophores.

1        37. The method of claim 36, wherein the BODIPY® fluorophores are  
2        selected from the group of BODIPY® 530/550; BODIPY® 503/512;  
3        BODIPY® 564/570; BODIPY® 589/616; BODIPY® 581/591; BODIPY®  
4        523/547; BODIPY® 558/568; and BODIPY® 576/589.

1        38. The method of claim 36, wherein said deoxyadenosine triphosphate  
2        is labeled with BODIPY® 523/547 or BODIPY® 530/550; said deoxycytidine  
3        triphosphate is labeled with BODIPY® 576/589, BODIPY® 581/591, or  
4        BODIPY® 589/616; said deoxyguanosine triphosphate is labeled with  
5        BODIPY® 503/512; and said deoxythymidine triphosphate is labeled with  
6        BODIPY® 558/568 or BODIPY® 564/570.

1        39. The method of claim 36, wherein said BODIPY® fluorophores have  
2        an adsorption maxima of about 450 to 700, and an emission maxima of  
3        about 450 to 700.

1        40. The method of claim 36, wherein said internal labelling and  
2        distinguishing polynucleotides is performed by an automated  
3        GeneScanner.

1        41. The method of claim 36, wherein said classes of polynucleotides are  
2        formed using a DNA polymerase selected from the group of Klenow  
3        fragment, Sequenase®, *Bst* DNA polymerase, AmpliTaq® DNA polymerase,  
4        *Pfu*(exo-)DNA polymerase, Thermosequenase®, *rTth* DNA polymerase or

5 Vent(exo-) DNA polymerase, and the reverse transcriptase is selected from  
6 the group of AMV-RT or M-MuLV-RT.

1 42. An oligonucleotide substituted with at least two 4,4-difluoro-4-bora-  
2 3A,4A-diaza-s-indacene (BODIPY®) fluorophores for performing a Taqman  
3 assay, wherein a first 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene  
4 (BODIPY®) fluorophore is a quencher fluorophore and a second 4,4-  
5 difluoro-4-bora-3A,4A-diaza-s-indacene (BODIPY®) fluorophore is a  
6 quenched fluorophore.

1 43. The oligonucleotide of claim 42, wherein said quencher fluorophore  
2 is BODIPY® 564/570 (4,4-difluoro-5-styryl-4-bora-3a,4a-diaza-s-indacene-3-  
3 propionic acid)

1 44. The oligonucleotide of claim 42, wherein said quencher fluorophore  
2 is BODIPY® 576/589 (4,4-difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-diaza-s-  
3 indacene-3-propionic acid).

1 45. The oligonucleotide of claim 42, wherein said quencher fluorophore  
2 is BODIPY® 581/591 (4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-  
3 3a,4a-diaza-s-indacene-3-propionic acid).

1 46. The oligonucleotide of claim 42, wherein said quenched fluorophore  
2 is BODIPY® 503/512-SE (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-  
3 indacene-3-propionic acid).

1 47. The oligonucleotide of claim 42, wherein said quenched fluorophore  
2 is BODIPY® 558/568 (4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-  
3 indacene-3-propionic acid).

-63-

- 1        48. The oligonucleotide of claim 42, wherein said quenched fluorophore  
2        is BODIPY® 589/616 (6-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-  
3        indacene-3-yl)phenoxy)acetyl)amino)hexanoic acid).
- 1        49. The oligonucleotide of claim 42, wherein said quenched fluorophore  
2        is BODIPY® 523/547 (4,4-difluoro-5-phenyl-4-bora-3a,4a-diaza-s-indacene-  
3        3-propionic acid).
- 1        50. The oligonucleotide of claim 42, wherein said quenched fluorophore  
2        is BODIPY® 530/550 (4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-  
3        indacene-3-propionic acid).
- 1        51. An oligonucleotide substituted with at least one 4,4-difluoro-4-bora-  
2        3A,4A-diaza-s-indacene (BODIPY®) fluorophore for performing a Taqman  
3        assay, wherein said at least one 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene  
4        (BODIPY®) fluorophore is a quenched fluorophore and a quencher agent  
5        is present in said Taqman assay.
- 1        52. The oligonucleotide of claim 51, wherein said quenched fluorophore  
2        is BODIPY® 589/616 (6-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-  
3        indacene-3-yl)phenoxy)acetyl)amino)hexanoic acid).
- 1        53. The oligonucleotide of claim 51, wherein said quenched fluorophore  
2        is BODIPY® 523/547 (4,4-difluoro-5-phenyl-4-bora-3a,4a-diaza-s-indacene-  
3        3-propionic acid).
- 1        54. The oligonucleotide of claim 51, wherein said quenched fluorophore  
2        is BODIPY® 530/550 (4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-  
3        indacene-3-propionic acid).

1/20




Figure 1A

2/20





Figure 1B



**Figure 2A**

**Figure 2B**

5/20




Figure 3A

6/20




Figure 3B

7/20




Figure 3C

8/20




Figure 3D

9/20




Figure 3E


SUBSTITUTE SHEET (RULE 26)

10/20

Conventional sequencing primers: No mobility correction

AAT T A A A C G A G N C C G T C A C  
T G T T G C C C R A I A I I G G A T G C  
H N G N G G N G C N T A A I I G G A T G C  
H H H H H H H H H H H H H H H H H H H H

110-130 bases  
200-220 bases



**Figure 4A**

11/20




Figure 4B

12/20




Figure 4C


13/20  
Route I

Figure 5A

14/20

## Route II




Figure 5B

**SUBSTITUTE SHEET (RULE 26)**

15/20




Figure 6A

SUBSTITUTE SHEET (RULE 26)

16/20






Figure 6B

17/20




ATP-BODIPY




GTP-BODIPY

Figure 7A

18/20



CTP-BODIPY



UTP-BODIPY

Figure 7B

19/20

BET-6/3



Figure 8A

SUBSTITUTE SHEET (RULE 26)

20/20

## RT resistant markers




Figure 8B

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/10729

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12P 19/34; C12Q 1/68, 1/70; C07H 19/04  
 US CL :435/91.1, 91.2, 6, 5; 536/26.6

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/91.1, 91.2, 6, 5; 536/26.6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,274,113 (KANG ET AL.) 28 December, 1993, see entire document.	1-54
Y	EP, A2, 0 233 053 (APPLIED BIOSYSTEMS) 19 August 1987, see entire document.	1-54
Y	US, A, 5,366,860 (BERGOT ET AL.) 22 November 1994, columns 1-3.	1-54
Y, E	US, A, 5,538,848 (LIVAK ET AL.) 23 July 1996, see columns 1-2	42-54
A	US,A 5,202,231 (DRMANAC ET AL.) 13 April 1993, see entire document.	19-21

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*'A'	document defining the general state of the art which is not considered to be of particular relevance	
*'E'	earlier document published on or after the international filing date	"X"
*'L'	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"
*'O'	document referring to an oral disclosure, use, exhibition or other means	
*'P'	document published prior to the international filing date but later than the priority date claimed	"&"

Date of the actual completion of the international search

02 AUGUST 1996

Date of mailing of the international search report

05 SEP 1996

Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DIANNE REES

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/10729
---

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Nucleic Acids Research, Volume 20, Number 10, issued 1992, L.G. Lee et al, "DNA sequencing with dye-labeled terminators and T7 DNA polymerase: effects of dyes and dNTPs on incorporation of dye-terminators and probability analysis of termination fragments", pages 2471-2483, see Figures 3-5.	1-54
Y	US, A, 4,318,846 (KHANNA ET AL.) 09 March 1982, see entire document.	42-54
A	Proceedings of the National Academy of Sciences, Volume 91, issued May 1994, A.C. Pease, " Light-generated oligonucleotide arrays for rapid DNA sequence analysis", pages 5022-5026, see entire document.	19-21
Y	US, A, 5,151,507 (HOBBS, JR. ET AL.) 29 September 1992, see entire document.	25-41
Y	US, A, 5,241,060 (ENGELHARDT ET AL.) 31 August 1993, see entire document.	25-41

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US96/10729

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS, CAPLUS, BIOTECHDS, BIOTECHABS, MEDLINE, TOXLINE, TOXLIT, WPIDS, USPATFULL,  
DRUG, DISSABS, SCISEARCH

search terms: BODIPY, sequencing, CGE, capillary gel electrophoresis, SBH, sequencing by hybridization, Taqman,  
linkers, quenching, FET, searched structures.